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Ataxia telangiectasia-mutated (ATM) is a serine/threonine protein kinase that has critical 
functions in the cellular responses to DNA damage, including cell cycle checkpoint activation 
and DNA repair. Since ataxia telangiectasia individuals, who have homozygous mutations in 
ATM, are exquisitely radiosensitive there is considerable interest in inhibiting the kinase activity 
of ATM to increase the efficacy of targeted radiotherapy. In this dissertation work, I sought to 
understand the cellular responses to radiation when ATM kinase activity is transiently inhibited 
using the small molecule ATM kinase inhibitor KU55933.  During my PhD, our laboratory has 
shown that transient ATM kinase inhibition one hour post-irradiation results in 
radiosensitization, increased chromosome aberrations and abrogation of sister chromatid 
exchange.  I contributed to these findings by showing that the cellular radiosensitization seen in 
H460 cells with kinase-inhibited ATM was identical to that seen when ATM protein was 
disrupted using siRNA prior to the insult.  In addition, I demonstrated that 15 minutes of ATM 
kinase activity post-irradiation is sufficient to trigger the G2/M cell cycle checkpoint, and that 
subsequent transient inhibition of ATM with KU55933 does not affect recovery from this 
checkpoint. To gain a more global view of the functional consequences of kinase-inhibited ATM 
following irradiation, I utilized a SILAC-based tandem mass spectrometry approach, combined 
with a subcellular fractionation protocol, to determine ATM kinase-dependent spatial proteome 
dynamics in response to radiation-induced DNA damage. Analysis of the chromatin-associated 
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 v 
proteome revealed that the retention of 53BP1 at chromatin is decreased when the kinase activity 
of ATM is inhibited following ionizing radiation (IR). Using fluorescence recovery after 
photobleaching in live cells, I determined that the stability of IR-induced GFP-53BP1 foci is 
decreased when the kinase activity of ATM is inhibited following IR. These results provide a 
roadmap for understanding ATM kinase-dependent spatial protein dynamics in response to DNA 
damage. 
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1.0  INTRODUCTION 
 
1.1 ATAXIA TELANGIECTASIA (A-T)  
Ataxia telangiectasia (A-T) is an autosomal recessive disorder characterized by 
progressive neurodegeneration, oculocutaneous telangiectasia, defects in B and T cell–mediated 
immunity, increased susceptibility to malignancies (mainly lymphoid neoplasms) and 
radiosensitivity.1,2 A-T is a rare disease, with an incidence of 1 to 2.5 in 100,000.3,4 A-T is 
caused by biallelic mutations in the ATM gene, which is located at 11q22.3 and covers 160 kb of 
genomic DNA.5 The ATM protein is produced from a 13 kb transcript that encodes for a protein 
that is predicted to be 315 kDa, but migrates at approximately 370 kDa on SDS-PAGE.5 ATM is 
a protein kinase, and cells derived from patients with the classical A-T phenotype lack ATM 
kinase activity as a result of either compound heterozygosity or, less frequently, homozygosity 
for truncating mutations (frameshift or nonsense mutations). In both cases, the mutations result 
in an absence of stable ATM protein.6,7 Radiosensitivity (increased cell death following ionizing 
radiation exposure) was first documented when an A-T patient with cancer had a toxic reaction 
to radiation therapy, and is now considered a salient feature of A-T.8 Cells derived from A-T 
patients exhibit defective cell cycle checkpoint responses to ionizing radiation (IR), profound 
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radiosensitivity, and high levels of chromosome aberrations, indicating the importance of ATM 
for the maintenance of chromosome stability and radioprotection.2  
1.2 THE PIKK FAMILY 
ATM is a member of phosphoinositide 3-kinase-related protein kinase (PIKK) family, 
which also includes ATR (ATM and rad3 related protein kinase), DNA-PKcs (DNA-dependent 
protein kinase catalytic subunit), mTOR (mammalian target of rapamycin), and hSMG1.5,9 The 
PIKK family of proteins are large proteins (2547 to 4128 amino acids) and serine/threonine 
protein kinases that share a C-terminal protein kinase domain, flanked by an N-terminal FAT 
(FRAP, ATM, TRRAP) domain composed of HEAT (Huntingtin, Elongation factor 3, A subunit 
of protein phosphatase 2A and TOR1) repeats, and a C-terminal FATC (FAT C-terminus) 
domain (Figure 1).9 The FATC domain is a small domain comprised of 32 amino acids that is 
required for PIKK kinase activity 9. Since the FAT and FATC domains flank the PIKK kinase 
domain it has been suggested that they interact and function in kinase regulation 10. There is little 
sequence similarity between the kinases outside of these common domains; the remainder of 
each protein consists of more HEAT repeats that may serve as protein–protein interaction 
surfaces 9,11. ATM, ATR and DNA-PKcs have roles in DNA repair and are activated by DNA 
lesions: DNA double-strand breaks (DSBs) activate ATM and DNA-PKcs, and single-stranded 
DNA (ssDNA) gaps activate ATR 9.  
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Figure 1. The phosphoinositide 3-kinase-related protein kinase (PIKK) family 
 
 
Although ATM, DNA-PKcs and ATR all have affinity for nucleic acids, they required 
proteins or protein complexes that directly bind DNA for DNA lesion recognition. The Mre11-
Rad50-Nbs1 (MRN) complex recruits ATM to DSBs, the Ku70-Ku80 protein complex recruits 
DNA-PKcs to DSBs and ATRIP recruits ATR to ssDNA via its interaction with the ssDNA 
binding protein RPA 12-14. The N-terminal HEAT repeat region of each PIKK serves as the 
binding site for the recruitment complexes, and is mediated through a common motif near the C-
terminus of Nbs1, Ku70, and ATRIP 9,15. 
1.3 ATM KINASE ACTIVITY 
ATM is a serine/threonine protein kinase with a consensus phosphorylation motif of 
hydrophobic-X-hydrophobic-[S/T]-Q. ATM kinase activity is rapidly stimulated in cells exposed 
to ionizing radiation (IR). 16-18 ATM kinase activation is associated with autophosphorylation on 
serine-1981, which is an exceptionally sensitive marker for ATM kinase activity in cells.16 ATM 
modifed from DNA Repair. 2009 Sep 2;8(9)1004-8.
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kinase activity is increased in cells exposed to as little as 0.05 Gy IR and following the 
introduction of just two DSBs per cell.16,19 Following 0.4 Gy IR, ATM kinase activity is maximal 
within 15 minutes, at which point over 50% of ATM is phosphorylated in cells.16  
A considerable body of literature documents the ATM kinase-dependent mobilization, 
modification and upregulation of proteins critical for the induction of cell cycle checkpoints and 
apoptosis following IR. Over 1,000 ATM and ATR kinase-dependent phosphorylations have 
been identified in cells exposed to IR.20-22 ATM kinase-dependent phosphorylations have been 
found to modify proteins involved in DNA replication, DNA repair, cell cycle progression, and 
numerous signaling pathways.20-22 Despite these efforts, the indispensable ATM kinase-
dependent mechanisms that ensure genome stability and cell survival are not well understood. 
Isolating changes in protein function that are causally related to A-T or its cellular phenotypes 
may be particularly challenging since stress-activated kinases such as ATM have little selective 
pressure to restrict functionally insignificant phosphorylations. 
1.4 ATM KINASE ACTIVITY IN CELL CYCLE CHECKPOINTS 
ATM kinase activity is essential for the induction of cell cycle checkpoints during S-
phase and at the G1/S and G2/M boundaries following IR. Cell cycle checkpoints prevent cell 
cycle progression in the presence of chromosome damage and allow sufficient time for 
chromosome repair.23 One of earliest cellular phenotypes described in A-T cells was a defect in 
the intra-S-phase checkpoint.24 A-T cells lack the ability to inhibit DNA synthesis following 
irradiation, a phenomena described as “radioresistant DNA synthesis.”24 ATM kinase-dependent 
phosphorylations on BRCA1, FANCD2 and NBS1 have been implicated in the intra-S-phase 
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checkpoint.25-27 Activation of the G1/S checkpoint following IR requires ATM kinase-dependent 
induction of FBXO31-mediated cyclin D1 degradation, and maintenance of the G1/S checkpoint 
requires the ATM kinase-dependent induction of p53-dependent p21 transcription.28-30  
The G2/M checkpoint following IR relies on the ATM kinase-dependent 
phosphorylations on BRCA1 and hRAD17.31-33 Cell cycle checkpoint abrogation in G2/M 
impairs the repair of chromosomal breaks in A-T cells.34 Notably, the G2/M checkpoint attracted 
considerable attention as a cancer therapeutic target since many cancer cells, like A-T cells, 
harbor defective G1/S checkpoints and cancer cells depend on the G2/M checkpoint far more than 
normal cells.35,36 Presumably, disruption of the G2/M cell cycle checkpoint by an ATM kinase 
inhibitor could increase the efficacy of radiotherapy and chemotherapies by allowing cancer cells 
containing damaged chromosomes to proceed directly into mitosis, thereby promoting 
chromosome instability, imbalanced cell division and ultimately cell death.37 However, several 
lines of evidence convey that the cellular radiosensitivity seen in A-T cells is not entirely 
attributed to defective cell cycle checkpoint activation.38-41 For example, irradiated A-T cells 
held in G0 for up to 18 hours, far longer than needed for maximum repair of radiation-induced 
DNA lesions, do not exhibit a reduction in the number of chromosome aberrations or cell 
death.38 Similarly, when aphidicolin is used to block the G1/S-phase transition in irradiated A-T 
cells, there is no evidence for a reduction in cell death.39 Furthermore, the use of premature 
chromosome condensation (PCC) has shown that irradiated A-T cells can be held continuously 
post-irradiation in G0 for up to 48 hours without evidence for a reduction in the number of 
chromosome aberrations.40 Finally, sublethal irradiation results in increased yields of 
chromosome aberrations in unstimulated A-T lymphocytes, but not normal lymphocytes.41 
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1.5 ATM KINASE ACTIVITY IN DNA REPAIR 
There is accumulating evidence that ATM kinase activity is required to phosphorylate 
substrates that function in the repair of DSBs. DSBs are repaired by two principal mechanisms: 
non-homologous end-joining (NHEJ) and homologous recombination (HR).42 HR is the most 
accurate DSB repair mechanism but is generally restricted to the S- and G2-phases of the cell 
cycle when DNA has been replicated and a sister chromatid is available as a repair template.43 
NHEJ operates throughout the cell cycle but assumes most importance in G1.44 The core NHEJ 
machinery includes DNA-PKcs, XRCC4, Ligase IV and Artemis.44 ATM kinase-dependent 
Artemis activity is implicated for the resolution of approximately 10% of DSBs that are repaired 
several hours following IR.45,46 While an ATM kinase-dependent phosphorylation on Artemis 
serine 645 has been identified, the phosphorylation site has not been found to have a function in 
DNA repair or cellular radioprotection.47  
Generally, HR repair of a DSB involves the processing of a DSB to give single-stranded 
DNA (ssDNA), formation of a filament on the ssDNA ends, strand invasion into a homologous 
sequence to form a D-loop and DNA polymerase extension.43 In mammalian cells, ATM kinase 
activity has been implicated in HR repair through numerous substrates. Disruption of ATM 
substrates DCK, EHMT1, FBXC11 and NUMA1 reduced the HR repair of an I-Sce-1-induced 
DSB.21 In addition, ATM kinase-dependent phosphorylations on MRE11, RAD50 and NBS1 
(MRN complex) have been identified.21,27 Finally, ATM kinase activity has also been implicated 
in DSB end resection via CtIP, which is also involved in the HR repair functions of the MRN 
complex.48-50  
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1.6 ATM  KINASE ACTIVITY AND CANCER 
Following exposure to ionizing radiation (IR), A-T cells display defective cell cycle 
checkpoints, residual chromosomal breaks, slower DNA double-strand break (DSB) rejoining 
than wild-type cells, and a failure to repair all DSBs, all of which could contribute to the 
radiosensitivity of A-T cells.40,51-53 Therefore, it has been proposed that inhibition of ATM may 
give rise to radiosensitization.37 Studies performed thus far indicate that selective ATM kinase 
inhibitors do in fact radiosensitize cells and therefore, may be effective agents in the treatment of 
cancers that are resistant to radiation therapy.54-56 
Recently, inhibition of ATM kinase activity has been shown to be toxic to cancer cells 
with somatic mutations in genes that are synthetic lethal with ATM kinase activity. Two genes 
are synthetic lethal if mutation of either gene alone is compatible with viability but mutation of 
both genes leads to death.57-59 The term “synthetic lethality” has been redefined to include 
synthetic lethal interactions between a mutated gene and a pharmacologically targeted gene. A 
synthetic lethal approach is advantageous for cancer therapy because pharmacologically 
targeting a gene that is synthetic lethal with a cancer-relevant mutation selectively kills cancer 
cells while sparing normal cells, thereby enhancing the therapeutic index (ratio of the toxic dose 
to the effective dose of a drug) between the tumor and normal tissue.57-59 A synthetic lethal 
approach also enables targeting tumors driven by loss-of-function mutations in tumor suppressor 
genes, which historically have been difficult to target by other strategies.60-63 Genotype-specific 
agents based on synthetic lethality can also be used as monotherapies, or to enhance the efficacy 
of cytotoxic therapies used at lower doses, thereby decreasing off-target side effects.60,64,65  
The paradigm for synthetic lethal approach for cancer is poly(ADP-Ribose) polymerase 
(PARP) inhibition in BRCA1-/- and BRCA2-/- tumors. PARP functions in the base excision 
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repair of DNA single-strand breaks (SSBs) and PARP inhibitors cause an accumulation of 
unrepaired SSBs that induce toxic DSBs via collapsed DNA replication forks.66 PARP inhibitors 
selectively kill BRCA-/- cancer cells, while sparing BRCA+/+ and BRCA+/- normal cells and 
show promise in the clinic for the treatment of patients with cancers associated with BRCA1 or 
BRCA2 mutations.67,68 
Several studies have reported synthetic lethal interactions with inhibition of ATM kinase 
activity. The ATM kinase inhibitor KU55933 has been shown to kill pancreatic tumor cell lines 
deficient in the Fanconi anemia (FA) pathway.69 The FA pathway, which functions in the repair 
of DNA interstrand crosslinks, is mutated in >10% of pancreatic cancers and >15% of lung 
cancers have inactivated FANCF.70,71 In addition, KU55933 has been shown to kill p53-deficient 
lung cancer cell lines when treated with doxorubicin, demonstrating a synthetic lethal interaction 
between ATM kinase signaling and p53 when cells are challenged with a DNA damaging 
agent.72,73 Future studies are needed to further elucidate the mechanisms underlying these 
synthetic lethal interactions. Given the high frequency of p53 or/and FA pathway mutations in 
cancers, these exciting findings highlight the potential therapeutic value of ATM kinase 
inhibitors.70,71,74  
In these studies, I sought to understand the cellular responses to radiation when ATM 
kinase activity is transiently inhibited using the small molecule ATM kinase inhibitor KU55933.  
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2.0  ATM KINASE INHIBITORS 
 
2.1 INTRODUCTION    
To date, three selective inhibitors of ATM kinase activity have been identified: 
KU55933, CP46672217 and KU60019.54-56 Prior to the discovery of these compounds, studies to 
test the consequences of ATM kinase inhibition in cells have utilized the nonspecific small 
molecules caffeine and wortmannin.75,76 However, caffeine and wortmannin inhibit related 
kinases including ATR, DNA-PK and PI3K at the concentrations required to inhibit ATM.76-81 
Moreover, the broad nonspecific effects of caffeine and wortmannin and the high effective 
concentration of caffeine (1 mmol/L) prohibit their use in the clinic.37 The advent of the selective 
ATM kinase inhibitors KU55933, CP46672217 and KU60019 enables preclinical studies to test 
the efficacy of ATM kinase inhibitors as anti-cancer agents.54 Furthermore, selective ATM 
kinase inhibitors are powerful tools for studying the role of ATM kinase signaling in the DNA 
damage response.54 The primary focus of my PhD has been to undertake preclinical studies using 
the ATM kinase inhibitor KU55933. Here, we test the effectiveness and reversibility of 
KU55933 and KU60019 in cells. In addition, we test the effectiveness of a controversial dual 
ATM/ATR kinase inhibitor, CGK733.82-84 
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2.2 BACKGROUND 
The first selective small molecule ATM kinase inhibitor KU55933 (2-morpholin-4-yl-6-
thianthren-1-yl-pyran-4-one) was identified by KuDOS Pharmaceuticals through screening a 
combinatorial library based around the nonspecific PI3K inhibitor LY294002 (Figure 2).54,77 The 
IC50 of KU55933 (i.e. the concentration of KU55933 that achieved 50% inhibition of ATM 
kinase activity) is 12.9 +/-0.1 nmol/L in vitro; the Ki is 2.2 nmol/L.54 Moreover, KU55933 
exhibits a 100-fold differential in selectivity for ATM over other members of the PIKK family in 
vitro.54 The ATM protein used in those in vitro assays were obtained from HeLa nuclear extracts 
by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 
amino acids of ATM.54  
KU55933 is a competitive ATP inhibitor.54 The morpholine oxygen in KU55933 is 
critical for ATM kinase inhibition; KU-58050, which replaces the morpholine moiety in 
KU55933 with a piperidine, had a calculated IC50 against ATM of 2.96 ± 0.44 µmol/L.54 Based 
on the crystal structure of the porcine PI3K p110γ subunit in complex with LY294002, it is 
conjectured that the morpholine acts through hydrogen bonding within the hinge region of the 
ATP-binding site of ATM.85 However, the crystal structure of ATM bound with KU55933 has 
not yet been reported.54 KU60019, the second-generation KuDOS Pharmaceuticals ATM kinase 
inhibitor, was developed in an effort to improve the bioavailability and pharmacokinetics of 
KU55933 while preserving its selectivity for ATM (Figure 2).56 KU60019 has an IC50 of 6.3 
nmol/L, 50% lower than that of KU55933, and an almost identical target spectrum as 
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KU55933.56 Importantly, off-target effects of KU55933 or KU60019 in cells at doses that inhibit 
ATM are yet to be demonstrated.  
 
 
Figure 2. Chemical structures of the ATM kinase inhibitors KU55933 and KU60019 
    
The Pfizer compound CP466722 [2-(6,7-dimethoxyquinazolin-4-yl)-5-(pyridin-2-yl)-2H-
1,2,4-triazol-3-amine] was identified by screening a library of 1,500 compounds using an in vitro 
ELISA approach which detects a decreased ability of purified ATM kinase to phosphorylate 
GST-p53 substrate.55 Like KU55933 and KU60019, CP466722 is a potent inhibitor of ATM and 
does not inhibit PI3K or PIKKs in cells at concentrations used to inhibit ATM.55  
A fourth compound, CGK733 was reported to inhibit both ATM and ATR kinase 
activities and block their checkpoint signaling with great selectivity (Figure 3).82 CGK733 was 
described as a small molecule capable of reversing replicative senescence.82 Senescence, which 
was induced in human primary BJ fibroblasts by overexpression of the dominant negative form 
of the telomeric t-loop formation protein Trf-2 (TRF1ΔBΔM), was monitored by automated 
fluorescence microscopy after adding compounds from a library of ~20,000 synthetic organic 
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molecules.82,86,87 CGK733 induced cell growth in the senescent cells and senescence markers 
such as the senescence-associated β-galactosidase activity disappeared in cells treated with 
CGK733. In addition, the removal of CGK733 reverted cells back to a senescent phenotype. In 
order to identify the molecular target of CGK733, the magnetism-based interaction capture 
(MAGIC) method was used and ATM was identified as the target of CGK733.82,88 CGK733 was 
reported to have an inhibitory effect on the kinase activity of ATM and ATR in vitro, and 
negligible effects on DNA-PK or any other kinases that are known to phosphorylate p53.82 Thus, 
CGK733 was discovered as a new small molecule inhibitor selective for ATM and ATR.82  
 
 
Figure 3. Chemical structure of the ATM and ATR kinase inhibitor CGK733 
 
Two years after publication, the paper reporting the identification of CGK733 and its 
molecular targets was retracted.83,84 An investigation by the Korean Advanced Institute of 
Science and Technology could find no evidence that the MAGIC screen to identify CGK733 as 
an anti-senescence agent was carried out and revealed that the subsequent experiments exploring 
the cellular effects of CGK733 utilized chemical compounds similar but not identical to 
CGK733.84 Yet, the retraction letter did not specifically address whether CGK733 is a bona fide 
ATM and/or ATR inhibitor and confusion ensued regarding the inhibitory effects of CGK733.84 
CGK733 continues to be commercially marketed by Sigma-Aldrich and Tocris Bioscience as an 
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ATM and ATR inhibitor. Indeed, several manuscripts employing CGK733 as an inhibitor of the 
kinase activities of ATM and/or ATR have been published in respected journals, in which no 
controls were presented to demonstrate that CGK733 inhibits the kinase activity of either ATM 
or ATR.89,90  
 
2.3 MATERIAL AND METHODS 
2.3.1 Cell lines, irradiation and inhibitor treatment 
The normal diploid fetal human lung fibroblast cell line IMR90 and the transformed lung 
cell line NCI-H460, which is wild-type for p53, were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). IMR90 were cultured in DMEM and H460 were cultured in 
RPMI, both supplemented with 10% FBS (Atlanta Biologicals). KU55933 and KU60019 
(KuDOS Pharmaceuticals) were reconstituted in DMSO and used at a 10 µM and 1µM, 
respectively. CGK733 (Tocris Bioscience and Sigma) was reconstituted in DMSO and used at 10 
µM. ETP-46464 at 10 µM in DMSO was a kind gift of Dr. Oscar Fernandez-Capetillo (Genomic 
Instability Group, Spanish National Cancer Centre, Madrid, Spain). Cells were γ-irradiated in a 
Shepherd Mark I Model 68 [137Cs] irradiator (J.L. Shepherd & Associates, San Fernando, CA).  
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2.3.2 Antibodies 
Rabbit monoclonal anti-ATM 1981S-P antisera (EP1890Y, Epitomics, Burlingame, CA), 
anti-ATM antisera (MAT3-4G10/8, Sigma-Aldrich, St. Louis, MO), anti-p53 (sc6243-G, Santa 
Cruz Biotechnology, Santa Cruz, CA), anti-P53 15S-P (9284, Cell Signaling Technology, 
Danvers, MA), anti-CHK2 (Ab5/DCS270, Neomarkers, Fremont, CA), anti-CHK2 68T-P (2661, 
Cell Signaling), anti-CHK2 (1C12, Cell Signaling), anti-CHK1 317S-P (2344, Cell Signaling), 
anti-CHK1 (2G1D5, Cell Signaling) and generic anti-HSC70 (sc-1059, Santa Cruz 
Biotechnology) were used in immunoblotting. Whole cell extracts were prepared in lysis buffer: 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM NaF, 50 mM NEM, 1% Tween-20, 0.5% NP40 
and 1 x protease inhibitor mixture (Roche Applied Science, Indianapolis, IN). Lysates were 
resolved in 3-8% Tris-Acetate gels (Invitrogen, Carlsbad, CA).  
2.4 RESULTS 
2.4.1 KU55933  
In order to determine the concentration of KU55933 that is required to inhibit ATM 
kinase activity in IMR90 cells, ATM serine 1981 phosphorylation, p53 protein levels and p53 
serine 15 phosphorylation were immunoblotted one hour following exposure to 5 Gy γ-rays. We 
used KU55933 at 10 µM since this concentration has been used previously to inhibit ATM 
kinase activity in a variety of cell types.54 Next, we determined the minimal amount of time prior 
to irradiation that cells needed to be incubated with 10 µM KU55933 to inhibit ATM kinase 
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activity in cells. ATM kinase activity was inhibited when 10 µM KU55933 was added to cells 5 
minutes prior to irradiation (Figure 4).19 We also determined the minimal amount of time for the 
removal of KU55933 prior to irradiation in order to recover ATM kinase activity in cells 
following incubation with 10µM KU55933 for one hour. ATM kinase activity was not inhibited 
when 10 µM KU55933 was removed from cells five minutes prior to irradiation (Figure 4).19 
Thus, the effective intracellular half-life of the ATM kinase inhibition by KU55933 in IMR90 
cells is less than one hour.19       
In order to more precisely determine the effective half-life of ATM kinase inhibition by 
KU55933 in IMR90 cells, ATM serine 1981 phosphorylation and CHK2 threonine 68 
phosphorylation were immunoblotted 15 minutes following exposure to 5 Gy γ-rays. Again, 
ATM kinase activity was inhibited when 10 µM KU55933 was added to cells five minutes prior 
to irradiation (Figure 4)19 Likewise, ATM kinase activity was not inhibited when 10 µM 
KU55933 was removed from cells five minutes prior to irradiation (Figure 4).19 The effective 
intracellular half-life of the ATM kinase inhibition by KU55933 in IMR90 cells is therefore less 
than or equal to 15 minutes.  
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Figure 4. KU55933 functions as a “molecular switch” in cells.  
A. ATM kinase activity is inhibited in IMR90 cells one hour following irradiation when 10 µM KU55933 is added 
to the cells five minutes prior to the irradiation. 10 µM KU55933 was added at the time indicated before the 
irradiation and left on the cells until lysis. B. ATM kinase activity is undiminished in IMR90 cells one hour 
following exposure to 5 Gy γ-rays when 10 µM KU55933 is removed from the cells five minutes prior to the 
irradiation. Cells were exposed to 10 µM KU55933 for one hour culminating at the time indicated prior to the 
irradiation (-120 min -60 min, -90 min to -30 min, -75 min to 15 min and -65 min to -5 min). Media containing 
KU55933 was then removed and replaced with pre-conditioned media.  KU55933 was added to the control samples 
at -30 minutes and left on the cells.  C/D. Black bars indicate when KU55933 was on the cells in A and B, 
respectively. E. ATM kinase activity is inhibited in IMR90 cells 15 minutes following exposure to 5 Gy γ-rays when 
10 µM KU55933 is added to the cells five minutes prior to the irradiation. 10 µM KU55933 was added at the times 
indicated before the irradiation and left on the cells until lysis. F. ATM kinase activity is undiminished in IMR90 
cells 15 minutes following exposure to 5 Gy γ-rays when 10 µM KU55933 is removed from the cells five minutes 
prior to the irradiation. Cells were exposed to 10 µM KU55933 for one hour culminating at the time indicated prior 
to the irradiation (-120 min -60 min, -90 min to -30 min, -75 min to 15 min and -65 min to -5 min). Media 
containing KU55933 was then removed and replaced with pre-conditioned media.  KU55933 was added to the 
control samples at -30 minutes and left on the cells. G/H. Black bars indicate when KU55933 was on the cells in E 
and F, respectively. 
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2.4.2 KU60019  
Studies were performed to determine the effective intracellular half-life of KU60019 
indicate that KU60019 also functions as a molecule switch to inhibit ATM kinase activity in 
cells.91 When 1 µM KU60019 was added to IMR90 cells five minutes prior to the irradiation, 
ATM kinase activity was inhibited 15 minutes following irradiation (Figure 5).91 ATM kinase 
activity was restored in IMR90 fibroblasts 15 minutes following exposure to 5 Gy IR when 1 µM 
KU60019 was removed from fibroblasts five minutes prior to the irradiation (Figure 5).91  
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Figure 5. KU60019 functions as a “molecular switch” in cells. 
A. ATM kinase activity is inhibited in IMR90 fibroblasts 15 min following irradiation when 1 µM KU60019 is 
added to fibroblasts 5 min prior to the irradiation. 1 µM KU60019 was added at the time indicated before the 
irradiation and left on the cells until lysis. B. ATM kinase activity is undiminished in IMR90 fibroblasts 15 min 
following exposure to 5 Gy IR when 1 µM KU60019 is removed from fibroblasts 5 min prior to the irradiation. 
Cells were exposed to 1 µM KU60019 for a 1 h period culminating at the time indicated prior to the irradiation (-
120 min to -60 min, -90 min to -30 min, -75 min to -15 min and -65 min to -5 min). Media containing 1 µM 
KU60019 was then removed and replaced with preconditioned media. 1 µM KU60019 was added to the control 
samples at -30 min and left on the cells. 
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2.4.3 CGK733 
To test whether CGK733 inhibits ATM or ATR kinase activity in cells, we determined 
the effects of CGK733 on cells exposed to either ionizing radiation (IR) or ultraviolet radiation 
(UV). We examined the well-characterized IR-inducible ATM kinase-dependent 
phosphorylations on ATM serine 1981 and CHK2 threonine 68 to determine whether CGK733 
inhibits the kinase activity of ATM.16,92 H460 human lung cancer cells were treated with 10 µM 
CGK733, 10 µM KU55933 or 1 µM KU60019 and exposed to 5 Gy γ-rays. H460 were used 
because we have previously documented the ATM-dependent effects of both KU55933 and 
KU60019 in these cells and we selected a concentration of 10 µM CGK733 because this is the 
higher dose reported to inhibit the kinase activities of ATM and ATR in human cells.19,82,89-91 We 
observed that 10 µM CGK733 did not inhibit the IR-induced phosphorylation of either ATM 
serine 1981 or CHK2 threonine 68 one hour following irradiation whereas both 10 µM KU55933 
and 1 µM KU60019, which served as positive controls for the experiment, abrogated both the IR-
induced phosphorylation of ATM serine 1981 and CHK2 threonine 68 (Figure 6). Similar results 
were obtained using CGK733 purchased from Sigma-Aldrich (data not shown). We conclude 
that, contrary to previous reports, 10 µM CGK733 does not inhibit the kinase activity of ATM 
under these conditions.  
In order to determine whether CGK733 inhibits the kinase activity of ATR we examined 
the phosphorylation of ATM on serine 1981 and the well-characterized UV-induced 
phosphorylation on CHK1 serine 317.93 To date, three selective inhibitors of ATR kinase activity 
have been identified: 45, VE-821 and ETP-46464.94-96 We treated H460 cells with 10 µM 
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CGK733 (Tocris Biosciences) or 10 µM ETP-46464 and exposed cells to 10 J/m2 UV radiation. 
We observed that 10 µM CGK733 did not inhibit the UV-induced phosphorylation of CHK1 
serine 317 six hours following irradiation whereas 10 µM ETP-46464, which served as a positive 
control for the experiment, abrogated the UV-induced phosphorylation of CHK1 serine 317 
(Figure 6). Furthermore, the phosphorylation of ATM serine 1981 was increased in cells 
incubated in 10 µM ETP-46464 that were exposed to 10 J/m2 UV radiation. This observation has 
been reported previously and is consistent with a model in which inhibition of the kinase activity 
of ATR results in an accumulation of double-strand DNA breaks, perhaps due to the disruption 
of protein complexes that protect stalled replication forks from endonucleases.95 We conclude 
that, contrary to previous reports, 10 µM CGK733 does not inhibit the kinase activity of ATR 
under these conditions. We have been unable to demonstrate any inhibition of either the kinase 
activity of ATM or ATR by CGK733. 
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Figure 6. CGK733 does not inhibit ATM or ATR kinase activity in cells.  
A. Immunoblots of IR-inducible ATM kinase-dependent phosphorylations on ATM serine 1981 and CHK2 
threonine 68. H460 cells were treated with 10 µM CGK733, 10 µM KU55933 or 1 µM KU60019 from 30 min prior 
to exposure to 5 Gy γ-rays until harvest at 60 min following the insult. Lysates were resolved in 3-8% Tris-Acetate 
1D SDS-PAGE gels and immunoblotted with anti-ATM 1981S-P, anti-ATM, anti-CHK2 68T-P and anti-CHK2. 
B. Immunoblots of the phosphorylation of ATM on serine 1981 and ultraviolet radiation (UV)-induced 
phosphorylation on CHK1 serine 317. H460 human lung cancer cells were treated with either 10 µM CGK733 or 10 
µM ETP-46464 from 30 min prior to exposure to 10 J/m2 UV radiation until harvest at 6 h min following the insult. 
Lysates were resolved in 3-8% Tris-Acetate 1D SDS-PAGE gels and immunoblotted with anti-ATM 1981S-P, anti-
ATM, anti-CHK1 317S-P and anti-CHK1. 
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2.5 CONCLUSIONS                
 
We demonstrate that KU55933 and KU60019 can be used as “molecular switches” to 
selectively and transiently inhibit ATM kinase activity in cells.  ATM kinase activity is inhibited 
in irradiated cells within 15 minutes of the addition of KU55933 or KU60019 and is restored 
within 15 minutes following the removal of KU55933 or KU60019 from cells. This distinctive 
attribute of KU55933 and KU60019 allows for studies designed to dissect the temporal 
requirement(s) for ATM kinase activity relative to the time of genotoxic exposure. 
Importantly, we also show that CGK733 is not an ATM or ATR kinase inhibitor in cells. 
CGK733 does not inhibit ATM kinase signaling in H460 cells exposed to IR and CGK733 does 
not inhibit ATR signaling in H460 cells exposed to UV. We recognize that we did not use the 
same cell lines used in original CGK733 paper or in the subsequently published studies that have 
employed CGK733.82,89,90 Thus, we acknowledge that, although unlikely, there is always the 
possibility that H460 may have a unique genetic background that prevents CGK733 from 
functioning as an ATM or ATR kinase inhibitor. Regardless, the demonstration that CGK733 
does not inhibit ATM or ATR kinase activity in a cell line with intact ATM and ATR signaling 
warrants that proper controls be shown in future publications in which CGK733 is used to 
demonstrate that ATM or ATR kinase activities are actually inhibited.  
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3.0  CONSEQUENCES OF TRANSIENT ATM KINASE INHIBITION 
3.1 INTRODUCTION 
We previously showed that KU55933 can be used as a “molecular switch” to transiently 
inhibit ATM kinase activity in cells.91 This attribute of KU55933 facilitates studies that 
temporally dissociate ATM kinase-dependent signaling and function(s).  Here, we use KU55933 
to isolate a temporal window, +15 minutes to +75 minutes following irradiation, during which 
ATM kinase activity is required for radioprotection. We also use KU55933 to dissociate an ATM 
kinase-dependent DNA repair mechanism from an ATM kinase-dependent cell cycle checkpoint 
mechanism. We show that ATM kinase inhibition from +15 minutes to +75 minutes following 
irradiation causes significant cellular phenotypes: cellular radiosensitivity, increased 
chromosome aberrations in late-S- and G2-phases of the cell cycle and abrogation of sister 
chromatid exchange.  
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3.2 BACKGROUND 
ATM encodes a protein kinase that is critical for the initiation of DNA damage responses 
in mammalian cells exposed to ionizing radiation (IR) and other agents that introduce double-
strand breaks into DNA.17,18,97 Cells derived from ataxia-telangiectasia (A-T) patients, who lack 
the ATM protein, exhibit defective cell cycle checkpoint responses, increased chromosome 
aberrations and increased cell death following IR, thus revealing the importance of ATM-
dependent signaling in irradiated cells.2 
ATM kinase activity is essential for the induction of DNA damage-induced cell cycle 
checkpoints. Within seconds of exposure to IR, ATM phosphorylates and activates downstream 
effector kinases, including checkpoint kinase 2 (CHK2), as well as numerous other substrates, 
and such modifications cause an arrest of the cell cycle at the G1/S-phase and G2/M-phase 
transitions.24,29,33,92 DNA damage-induced cell cycle checkpoints were envisioned as a means to 
allow time for chromosome repair, thereby indirectly promoting chromosomal stability.23 
However, several lines of evidence suggest that the chromosomal instability of A-T cells is not 
entirely due to defective cell cycle checkpoints. For example, chromosome aberrations 
accumulate in irradiated A-T cells arrested in G0 for up to 48 hours indicating this damage is not 
a consequence of defective cell cycle checkpoints.38,40 Furthermore, when aphidicolin was used 
to block the G1/S-phase transition in A-T cells, no decrease in cell death was observed following 
IR.40 Since increased chromosome aberrations and cell death were evident in cells that were not 
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progressing through the cell cycle, these data are indicative of a DNA repair defect in A-T cells 
that is independent of cell cycle checkpoints.  
ATM kinase activity has also been shown to have direct roles on DNA repair. DNA 
double-strand break (DSB) repair can occur through two mechanisms: homologous 
recombination (HR) repair and nonhomologous end joining (NHEJ).42 HR is a high fidelity DSB 
repair mechanism that is generally restricted to the S- and G2-phases of the cell cycle when a 
sister chromatid is available as a repair template.43 ATM promotes the HR-mediated repair of 
DSBs in various systems, including in DT40 chicken cells in response to IR and in Chinese 
hamster cells in response to inhibition of poly ADP ribose polymerase (PARP).98,99 Furthermore, 
ATM kinase activity has been reported to participate in DSB end resection, a key initiating step 
in HR.48 Nevertheless, sister chromatid exchange (SCE), which is believed to be a cytological 
manifestation of HR at replication forks, is normal in A-T cells.100-102 Therefore, the contribution 
of ATM to HR-mediated repair appears to be dispensible at replication forks. 
NHEJ operates throughout the cell cycle but assumes most importance in G1 when a 
sister chromatid is not available as a repair template.44 The NHEJ machinery includes the DNA-
dependent protein kinase (DNA-PK), a heterotrimer comprising a catalytic subunit and KU70 
and KU80.44 Additional components attributed to NHEJ machinery include the LIG IV/XRCC4 
complex that has ligase activity, and also the Artemis endonuclease.44 Previously, ATM kinase 
activity was implicated in NHEJ through its phosphorylation of Artemis.45,46 ATM-dependent 
Artemis activity is required for the resolution of ~10% of DSBs by NHEJ in non-cycling G0 cells 
with slow kinetics (i.e. repaired within several hours following IR).45 Recently, ATM and 
Artemis have been reported to repair approximately 15% of IR-induced DNA double-strand 
breaks in G2 cells through a HR repair mechanism also occurring with slow kinetics.103 
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Therefore, ATM and Artemis can function in a slow-repair process involving NHEJ or HR repair 
depending on the cell-cycle phase.103 In these studies, the roles of ATM and Artemis in DNA 
double-strand breaks appear to represent the repair of DSBs located within or close to regions of 
heterochromatin.103 Whereas, ATM-Artemis activity in heterochromatin involves DNA end-
processing, ATM kinase also functions to relax heterochromatin by phosphorylating KAP1 (the 
corepressor for Krüppel-associated box zinc finger proteins).104,105 Phosphorylated KAP1 spreads 
rapidly throughout chromatin and could thereby facilitate the entry of the DNA repair 
machinery.104 
The precise nature of the lesion that is dependent on ATM function for resolution is not 
entirely known and the indispensable ATM-dependent mechanisms that ensure chromosome 
integrity are not fully understood. Here, we use KU55933 to isolate a temporal window during 
which ATM kinase activity is critically required for radioprotection and genome stability. We 
then identify the ATM kinase-dependent functions that mediate radioprotection and genome 
stability during this interval. 
3.3 MATERIAL AND METHODS 
3.3.1 Cell lines, irradiation and inhibitor treatment 
The normal diploid fetal human lung fibroblast line IMR90 and non-small cell lung 
cancer cell line NCI-H460 were obtained from the American Type Culture Collection (ATCC). 
The A-T fibroblast cell line GM09607 was obtained from the Coriell Institute for Medical 
Research. H460 were cultured in RPMI supplemented with 10% FBS, and IMR90 and GM09607 
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were cultured in DMEM supplemented with 10% and 15% FBS, respectively. The Artemis-
defective fibroblast line (CJ179-hTERT) was cultured in MEM supplemented with 15% FBS. 
KU55933 was reconstituted in DMSO and used at a final concentration of 10 µM. Cells were γ-
irradiated in a Shepherd Mark I Model 68 [137Cs] irradiator (J.L. Shepherd & Associates) at a 
dose rate of 77.0 R/min. 
 
3.3.2 Clonogenic survival assay 
One thousand cells were seeded in 60 mm petri dishes and treated with increasing doses 
of IR four hours post-plating. After 10 days, colonies were stained with 10% Giemsa/PBS 
solution. A colony was defined as a cluster of ≥50 cells, presumably having formed from a single 
cell. All experiments were performed in triplicate, and error is reported as the standard error of 
the mean. 
 
3.3.3 siRNA transfections  
H460 cells were transfected with either 40 nM siRNA targeted against ATM (5’-
gcgccugauucgagauccutt-3’) or a control siRNA targeted against luciferase using Lipofectamine 
2000, according to the manufacturer’s instructions (Invitrogen). Four days following 
transfection, cells were trypsinized, counted and plated for clonogenic survival assays. Cells 
were also collected at this time to generate lysates to validate loss of ATM protein expression by 
immunoblot. 
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3.3.4 Chromosome aberration analysis 
T-25 flasks of IMR90 or H460 were exposed to increasing doses of irradiation 48 hours 
prior to being harvested with 50 nM calyculin A (Calbiochem, Gibbstown, NJ) for 30 minutes or 
250 nM colcemid (Irvine Scientific, Santa Ana, CA) for two to four hours. The cells were 
harvested and dropped onto slides using conventional methods, and then solid-stained for eight 
minutes in 10% Giemsa. Chromosome aberrations included: chromosome breaks, chromatid 
gaps or breaks, quadriradials, triradials, giants, rings, minutes, dicentrics, fragments and dots. For 
the purposes of analysis, chromosome breaks, radials, giants, rings and dicentrics were assigned 
twice the weight of the other aberrations, as they involve two chromatid events. The total 
weighted aberrations (TWA) were determined per cell for each treatment. The standard error of 
the mean was used as the estimate of error in the sample. 
3.3.5 G2/M cell cycle checkpoint analysis 
500,000 IMR90 fibroblasts were seeded in 60 mm dishes and exposed to 2 Gy irradiation 
24 hours later. Fibroblasts were harvested at +75 minutes, +4 hours, +8 hours, and +12 hours 
following IR.  For the time points at +4 hours, +8 hours, and +12 hours, the media containing 
KU55933 was removed at +75 minutes and replaced with pre-equilibrated media (media stored 
in a tissue culture flask overnight in an incubator set at 37° C and 5% CO2) containing 100 ng/ml 
nocodazole to trap fibroblasts as they entered mitosis. Floating fibroblasts (obtained from media 
or 1x PBS wash) and trypsinized fibroblasts were collected and fixed overnight at -20°C in ice-
cold 70% ethanol/1x PBS. Fixed fibroblasts were permeabilized on ice for eight minutes in 
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0.25% triton X-100/PBS. Permeabilized fibroblasts were blocked in 1% BSA/1x PBS for one 
hour, incubated with phospho-histone H3 (Ser10) Alexa Fluor® 647 conjugated antibody (Cell 
Signaling) for one hour and counterstained with propidium iodide (Roche). At least 50,000 
fibroblasts per condition were analyzed by flow cytometry (Dako CyAn) and data were analyzed 
using Summit software (Dako). All experiments were performed in triplicate and the experiment 
was performed three times. Error bars were based on standard error of the mean. 
3.3.6 Sister chromatid exchange (SCE) analysis 
IMR90 or A-T fibroblasts (GM09607) were exposed to one cycle substitution (20 hours) 
with 10 µM BrdU prior to exposure to 2 Gy IR. Fibroblasts were allowed to recover for an 
additional 20 hours following treatment prior to harvesting in 250 nM colcemid (Irvine 
Scientific) for four hours. Harvested fibroblasts were dropped onto slides using conventional 
methods and metaphase spreads were differentially stained for SCE analysis. In brief, slides were 
incubated in Hoechst 33258 for 10 minutes, immersed in 55°C 2xSSC while exposed to a black 
light at a distance of 10 cm for 15 minutes. Exposed slides were then stained in 4% Giemsa for 
10 minutes.  Non-centromeric SCEs were scored for 50 fibroblasts. The standard error of the 
mean was used as the estimate of error in the sample.  The experiments were performed two 
times. 
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3.4 RESULTS 
3.4.1 ATM kinase activity is essential from +15 minutes to +75 minutes following 
irradiation for cell survival 
We previously showed that the ATM kinase inhibitor KU55933 can be used as a 
“molecular switch,” as ATM kinase activity is inhibited within 15 minutes of the addition of 
KU55933 to cells, and ATM kinase activity is restored within 15 minutes of the removal of 
KU55933 from cells.19 We exploited this attribute of KU55933 to determine the critical window 
relative to the moment of IR during which ATM kinase activity is essential for radioprotection. 
Clonogenic survival assays were performed to determine the capacity of H460 cells to survive 
and replicate when ATM kinase activity was inhibited using 10 µM KU55933 for various 
intervals around an exposure to IR. The cellular radiosensitization seen when ATM kinase 
activity was inhibited for four hours (+15 minutes to +4 hours 15 minute) or one hour (+15 min 
to +75 min) accounted for 83% and 72%, respectively, of that seen when ATM kinase activity 
was inhibited for 17 hours (-45 minutes to +16 hours 15 minutes) following exposure to 5 Gy γ-
rays (Figure 7).19 The cellular radiosensitization seen when ATM kinase activity was inhibited 
for four hours (+15 minutes to +4 hours 15 minutes) or one hour (+15 minutes to +75 minutes) 
accounted for 70% and 33%, respectively, of that seen when ATM kinase activity was inhibited 
for 17 hours (-45 minutes to +16 hours 15 minutes) following exposure to 2.5 Gy γ-rays (Figure 
7).19 This shows that ATM kinase activity is required one hour following radiation for cell 
survival.  
To address the possibility of an off-target effect of KU55933 on cellular 
radiosensitization, we compared the effect of KU55933 versus ATM protein disruption on cell 
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survival. The specificity of KU55993 for ATM is supported by its ability to inhibit ATM with an 
IC50 of 13 nM as opposed to DNA-PK (IC50 = 2.5 µM), mTOR (IC50 = 9.3 µM), PI-3K (IC50 = 
16.6 µM), ATR (IC50 = > 100 µM) or PI-4K (IC50 = > 100 µM); moreover, 10 µM KU55933 
does not radiosensitize A-T cells.54 We confirmed that cellular radiosensitization of H460 cells 
seen with 10 µM KU55933 from +15 minutes to +75 minutes post-irradiation was identical to 
that seen when ATM protein was disrupted prior to the insult using siRNA (Figure 7).19 The 
ATM protein disruption attained using siRNA resulted in an approximately 80% reduction in 
ATM protein and the cellular radiosensitization seen when ATM kinase activity was inhibited 
from +15 minutes to +75 minutes accounted for 72% of that seen when ATM kinase activity was 
inhibited for 17 hours following 5 Gy γ-rays (Figure 7).19    
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Figure 7. Sustained ATM kinase activity is essential for radioprotection. 
A. Maximal radiosensitization is seen in H460 following 17 hours of 10 µM KU55933 treatment, from -45 min to 
+16 h 15min (irradiation at t=0). The cellular radiosensitization seen following four hours (+15 minutes to +255 
minutes) and one hour (+15 minutes to +75 minutes) treatments with 10 µM KU55933 accounted for 83% and 72%, 
respectively, of that following 17 hours of 10 µM KU55933 at 5 Gy γ-rays. At 2.5 Gy γ-rays the cellular 
radiosensitization seen following four hours and one hour treatments with 10 µM KU55933 accounted for 70% and 
33%, respectively, of that following 17 hours of treatment. B. The cellular radiosensitization seen in H460 cells 
when ATM kinase activity is inhibited using KU55933 from +15 min to +75 min is identical to that seen when ATM 
protein was disrupted using siRNA prior to the insult. H460 cells were mock-transfected or transfected with either 
siRNA targeted against ATM (5’-gcgccugauucgagauccutt-3’) or a control siRNA targeted against luciferase. After 
four days, cells were concurrently plated for clonogenic survival assays and preparation of whole cell extracts. C. 
ATM protein levels are selectively reduced by 80% by the ATM siRNA. At the time of irradiation of the clonogenic 
survival assays, which had been set up concurrently, whole cell extracts were prepared and immunoblotted for 
validation of siRNA-mediated ATM protein disruption. 
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3.4.2 ATM kinase activity is essential from +15 minutes to +75 minutes following 
irradiation to suppress chromosomal instability. 
Exponentially dividing IMR90 cells and H460 cells were treated with 10 µM KU55933 
from +15 minutes to +75 minutes following exposure to 2 Gy γ-rays. Cells were harvested 48 
hours later following an exposure to 250 nM colcemid, a microtubule inhibitor, or 50 nM 
calyculin A, which prematurely condenses chromatin allowing visualization of late-S-, G2- and 
M-phase cells. In both H460 and IMR90 cells, there was ~1 break per cell, irrespective of 
KU55933 post-treatment or IR, with the exception of the cells exposed to both KU55933 and IR. 
The number of chromosome aberrations in H460 and IMR90 cells was increased approximately 
two-fold in late-S- and G2-, but not M-phase, cells when ATM kinase was inhibited from +15 
minutes to +75 minutes following exposure to 2 Gy IR (Fig. 8).19 Approximately 83% of all 
aberrations are chromatid breaks in H460 cells and approximately 79% of all aberrations are 
chromatid breaks in IMR90 cells.19 
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Figure 8. Transient ATM kinase inhibition from +15 minutes to +75 minutes following 2 Gy IR increases 
chromosomal aberrations.  
The frequency of chromosome aberrations is increased 48 hours  following irradiation in KU55933 treated late-S 
and G2 cells. Cells were treated with 10 µM KU55933 from +15 minutes to +75 minutes following exposure to 2 Gy 
γ-rays. Cells were harvested 48 hours later following an exposure to 250 nM colcemid, a microtubule inhibitor, or 
50 nM calyculin A, which prematurely condenses chromatin, allowing visualization of late-S- and G2-phase cells. In 
order to compensate for differences in ploidy between cell lines, the total weighted aberrations per cell were 
compared. In both H460 (A) and IMR90 (B) cells, there was ~1 break per cell, irrespective of KU55933 post-
treatment or irradiation, with the exception of the cells exposed to both KU55933 and irradiation. H460 and IMR90 
cells exposed to both KU55933 and irradiation contained at least a two-fold increase in aberrations per cell. 
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3.4.3 15 minutes of ATM kinase activity following irradiation is sufficient to trigger the 
G2/M cell cycle checkpoint and ATM kinase inhibition +15 minutes to +75 minutes 
following irradiation does not affect G2/M cell cycle checkpoint recovery. 
Because transient ATM kinase inhibition from +15 minutes to +75 minutes following 
exposure of cells to 2 Gy γ-rays is sufficient to cause the accumulation of persistent chromosome 
aberrations in late-S and G2-, but not M-phase, cells, we hypothesized that the ATM kinase-
dependent G2/M cell cycle checkpoint may be induced within 15 minutes of exposure to 2 Gy γ-
rays. In order to test this hypothesis, we utilized a flow cytometry-based G2/M cell cycle 
checkpoint assay coupled with the microtubule inhibitor nocodazole to trap cells in mitosis.106 
We observed that induction of the G2/M cell cycle checkpoint occurred rapidly in IMR90 
fibroblasts treated with either KU55933 or vehicle from +15 min to +75 min following exposure 
to 2 Gy γ-rays, as indicated by the reduction of 4N cells positive for phosphorylated histone H3 
at +75 minutes (Figure 9).91 Furthermore, the recovery from the G2/M arrest in IMR90 
fibroblasts treated with KU55933 from +15 minutes to +75 minutes was comparable to that of 
vehicle controls at 4 hours, 8 hours and 12 hours following 2 Gy γ-rays (Figure 9).91 Thus, 15 
minutes of ATM activity is sufficient for the induction of the G2/M cell cycle checkpoint 
following 2 Gy γ-rays and transient inhibition of the kinase activity of ATM from +15 minutes to 
+75 minutes post-IR does not affect recovery from this cell cycle checkpoint.  
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Figure 9. Transient ATM kinase inhibition +15 minutes to +75 minutes following 2 Gy IR does not affect 
G2/M cell cycle checkpoint activation or recovery.  
IMR90 fibroblasts were treated with KU55933 from +15 minutes to +75 minutes following 2 Gy IR, KU55933 was 
removed, and the microtubule inhibitor nocodazole was added in order to prevent cells from exiting mitosis.  
Fibroblasts were collected at +75 minutes, 4 hours, 8 hours, and 12 hours following IR for flow cytometric analysis 
of DNA content (% mitosis reflects 4N fibroblasts positive for phosphorylated histone H3 at +75 minutes). 
Recovery from the G2/M checkpoint was not perturbed by addition of KU55933 from +15 to +75 min following 2 
Gy IR. All conditions were performed in triplicate and the experiment was performed three times. Error bars were 
based on the standard error of the mean. 
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3.4.4 ATM kinase inhibition +15 minutes to +75 minutes following irradiation abrogates 
irradiation-induced sister chromatid exchange  
Sister chromatid exchange (SCE) is believed to be a homologous recombination-
mediated mechanism for the repair of stalled and collapsed DNA replication forks, which arise 
naturally during DNA replication or can occur if cells are irradiated in G1 or S phase.107 The 
molecular mechanisms of SCE and the role of ATM in SCE are not well understood. SCE is 
normal in A-T cells, indicating that ATM is not required for SCE.100-102 Given that homologous 
recombination repair occurs in late-S- and G2-phase, we hypothesized that the increase in 
chromosome aberrations that is seen with ATM kinase inhibition from +15 minutes to +75 
minutes following irradiation can be attributed to defects in homologous recombination repair. 
To test this hypothesis, we compared the number of IR-induced SCEs in fibroblasts entering 
mitosis in the presence or absence of functional ATM.  
We used four hours of treatment (from +8 hours to +12 hours post-irradiation) with 
colcemid, initiated 8 hours following IR, to trap cells in mitosis since recovery from the G2/M 
arrest in IMR90 fibroblasts treated with KU55933 from +15 minutes to +75 minutes following 
IR was shown to be comparable to that of vehicle controls at four hours, eight hours, and 12 
hours following IR (Figure 9).91 We found that the IR-induced increase in SCE at 12 hours 
following IR was abrogated when cells were treated with KU55933 from +15 minutes to +75 
minutes post-IR (Figure 10).91 Importantly, SCE was not abrogated when ATM kinase activity 
was inhibited -45 minutes to +15 minutes following exposure to IR, indicating that IR-induced 
increase in SCE is not a consequence of mitotic recombination or a second round of DNA 
replication (Figure 10).91  
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Figure 10. KU55933 abrogates IR-induced SCE in IMR90 cells. 
Treatment with 10 µM KU55933 +15 minutes to +75 minutes following 2 Gy IR, but not -45 minutes to +15 
minutes following 2 Gy IR, abrogates IR-induced SCE in IMR90 human primary lung fibroblasts. 
 
 
To ensure that KU55933 does not have an “off-target” effect that disrupts SCE, we 
investigated the effect of KU55933 on SCE in irriadated GM09607 A-T fibroblasts, which lack 
ATM protein. We harvested the fibroblasts after a four hour treatment with colcemid (from +16 
hours to +20 hours), which was initiated 16 hours following IR, to trap cells in mitosis and the 
number of SCEs per cell was counted in 50 cells. Each experiment was performed two times. In 
unirradiated A-T fibroblasts, we observed ~12 SCEs per cell both in fibroblasts treated with or 
without the ATM kinase inhibitor (Figure 11).91 Inhibition of ATM activity also did not change 
the number of SCEs (~17) in A-T fibroblasts 20 hours following exposure to 2 Gy IR (Figure 
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11).91 Thus, KU55933 does not appear to have an “off-target” effect that disrupt SCE in A-T 
fibroblasts. Because IR-induced SCE is intact in A-T fibroblasts, an ATM-independent 
mechanism of SCE clearly exists (Figure 11).91,100-102 In addition, since KU55933 abrogates SCE 
in IMR90 fibroblasts, which have functional ATM protein, but not in A-T cells, which lack ATM 
protein, the cellular consequences of acute, transient inhibition of ATM kinase activity and 
chronic loss of ATM protein are distinct.91 
 
 
 
Figure 11. KU55933 does not abrogate SCE in A-T cells.  
Treatment with 10 µM KU55933 from +15 minutes to +75 minutes following 2 Gy IR has no effect on IR-induced 
SCEs in GM09607 A-T fibroblasts. 
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3.5 CONCLUSIONS 
Our finding that KU55933 can be used as a “molecular switch” to transiently inhibit 
ATM kinase activity in cells has facilitated unique analyses of ATM kinase-dependent signaling 
and function.19 We show here that the cellular radiosensitization seen when ATM kinase activity 
is inhibited for only 1 hour (+15 minutes to +75 minutes) following irradiation, accounts for over 
70% of the cellular radiosensitization seen when ATM kinase activity is inhibited for 17 hours (-
45 minutes to +16 hours 15 minutes).19 We also demonstrate that the number of chromosome 
aberrations in IMR90 and H460 cells, determined 48 hours following irradiation, is increased 
approximately two-fold in late-S- and G2-, but not M-phase, when ATM kinase is inhibited from 
+15 minutes to +75 minutes following exposure to 2 Gy γ-rays.19 The majority of these 
aberrations in H460 and in IMR90 cells are chromatid breaks, and it is important to highlight that 
the aberrations persist despite the fact that ATM kinase activity is restored at +75 minutes post-
irradiation when KU55933 is removed from cells 47 hours prior to the preparation of the 
chromosome spreads.19 These data indicate that chromosome damage accumulates very rapidly 
in the absence of ATM kinase activity +15 to +75 minutes post-irradiation and persists for 
days.19  
Our finding that the number of chromosome aberrations in IMR90 and H460 cells is 
doubled in late-S- and G2-, but not M-phase, suggested that the DNA damage that is formed as a 
consequence of transient ATM kinase inhibition induces an ATM kinase-dependent G2/M cell 
cycle checkpoint. This would be consistent with the report that restoration of ATM kinase 
activity in mature lymphocytes that have transiently lost ATM function leads to loss of cells that 
have accumulated terminally deleted chromosomes, a finding that identifies a requirement for 
ATM in faithful end joining as well as checkpoint activation to prevent the persistence and 
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transmission of DNA DSBs.108 We show here that 15 minutes of ATM kinase activity is 
sufficient to induce the G2/M cell cycle checkpoint in response to IR and that neither the 
activation nor the recovery of this IR-induced cell cycle checkpoint is affected by ATM kinase 
inhibition from +15 minutes to +75 minutes (Fig. 9).91 Using KU55933 to temporally dissect 
ATM kinase functions following irradiation, we have dissociated an ATM kinase-dependent 
DNA repair mechanism from an ATM kinase-dependent cell cycle checkpoint mechanism.91 
We next hypothesized that the increase in chromosome aberrations that is seen in late-S- 
and G2-phase with ATM kinase inhibition from +15 minutes to + 75 minutes following 
irradiation can be attributed to defects in homologous recombination repair given that 
homologous recombination repair of double-strand breaks occur in late-S- and G2-phases of the 
cell cycle. To test this hypothesis, we compared the number of IR-induced SCEs in fibroblasts 
entering mitosis in the presence or absence of functional ATM and show that the increase in SCE 
in irradiated fibroblasts was abrogated when ATM kinase activity was transiently inhibited from 
+15 minutes to +75 minutes following exposure to IR (Fig. 10).91 This result is surprising 
because DNA damage-induced SCE occurred in A-T fibroblasts (Fig. 11), suggesting that A-T 
fibroblasts have adapted to the loss of this function of ATM and can initiate SCE in response to 
DNA damage through an ATM-independent mechanism.91 That is to say, the cellular 
consequences of acute ATM kinase inhibition and adaptation to loss of ATM protein are 
different in S-phase cells.91,109  
Thus, we demonstrate that KU55933 can be used to temporally isolate and dissociate 
ATM kinase-dependent functions. Transient ATM kinase inhibition from +15 minutes to +75 
minutes following IR has severe cellular consequences: radiosensitivity, increased chromosome 
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aberrations in late-S- and G2-phases of the cell cycle and a defect in sister chromatid 
exchange.19,91  
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4.0  ATM KINASE ACTIVITY IN SPATIAL PROTEIN DYNAMICS 
4.1 INTRODUCTION 
DNA damage invokes the dynamic recruitment and assembly of proteins on damaged 
chromatin. ATM is a central kinase in the DNA damage response, but its effects on protein 
dynamics has not been well studied. Here, we use SILAC-based tandem mass spectrometry 
combined with a subcellular fractionation protocol to compare the proteomes of irradiated 
IMR90 cells treated with and without the selective ATM kinase inhibitor, KU55933, across four 
distinct subcellular fractions: cytoplasmic, soluble nuclear, chromatin and insoluble pellet. 
Analysis of the chromatin proteome shows that the retention of 53BP1 at damaged chromatin is 
decreased when cells are treated with KU55933. Using fluorescence recovery after 
photobleaching (FRAP), we show that the stability of GFP-53BP1 radiation-induced foci is 
decreased with KU55933. We also identify ANXA1 as a protein significantly enriched for 
protein-protein interactions with DNA damage response proteins. Following irradiation, in the 
presence of KU55933, ANXA1 levels are selectively decreased in the chromatin fraction, 
whereas cytoplasmic ANXA1 levels are unchanged with KU55933. These results provide a 
roadmap for understanding ATM kinase-dependent spatial protein dynamics in response to DNA 
damage. 
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4.2 BACKGROUND 
The DNA damage response is a complex network of signal transduction pathways that 
activate processes such as DNA repair, cell cycle checkpoints, transcriptional regulation and 
chromatin reorganization in order to ensure cellular homeostasis and survival.110-112 Key to the 
DNA damage response is ataxia telangiectasia-mutated (ATM), a 370 kilodalton serine/threonine 
protein kinase that is activated by agents that cause DNA double-strand breaks (DSBs).113 Once 
activated, ATM phosphorylates substrates involved in DNA replication, DNA repair, cell cycle 
progression as well as other signal transduction pathways.113 Loss of ATM protein due to 
mutations in the ATM gene results in ataxia telangiectasia (A-T), a human disease characterized 
by exquisite radiosensitivity and predisposition for cancer.1,113 Global proteomic studies on ATM 
and the related kinase ATR have been aimed at identifying direct and indirect phosphorylation 
targets and have led to the identification of over 1,000 ATM and ATR substrate phosphorylation 
sites in cells.20-22 However, the role of ATM kinase activity on the spatial dynamics of proteins in 
response to DNA damage has not been explored.  
The DNA damage response is characterized by orchestrated spatial and temporal 
dynamics that are essential for an effective DNA repair.114,115 Following exposure to genotoxic 
agents, proteins are rapidly mobilized and loaded onto damaged chromosomes, assembling 
protein complexes that mediate DNA repair.114,115 Following irradiation, ATM phosphorylates 
histone H2AX, which is required to sustain the retention of repair proteins on H2AX-marked 
chromatin.116,117 The concentration of these recruited proteins at chromatin amplifies ATM 
signaling and presumably increases the efficiency of DNA repair.116,117 There is also precedent 
for ATM kinase regulation of protein dynamics across subcellular compartments. ATM kinase 
activity has previously been shown to regulate the localization of the deubiquitinase USP10.118 
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Following irradiation, USP10 translocates from the cytoplasm to the nucleus and stabilizes 
p53.118 ATM kinase-dependent phosphorylation of USP10 at Thr42 and Ser337 regulates the 
translocation and stabilization of USP10.118 Thus, ATM kinase-dependent relocalization of 
USP10 suppresses tumor growth by regulating the subcellular localization of p53.118 USP10 
deubiquitinates p53, reversing Mdm2-mediated p53 nuclear export and degradation.118 
Multiple examples from human diseases show that defects in the recruitment and 
retention of DNA damage proteins on chromatin result in genome instability and cancer 
indicating that spatial protein dynamics have crucial functions in human health. Defects in the 
recruitment of BRCA1, the major human hereditary breast cancer susceptibility protein, result in 
breast cancer.69,119 Defects in the loading of DNA interstrand crosslink repair proteins on 
chromatin cause the genome instability syndrome Fanconi Anemia.69,119-121 Therefore, 
identifying proteins that are spatially regulated by ATM kinase activity could reveal additional 
functions for ATM in the DNA damage response which are clinically significant. 
Here we use stable isotope labeling in cell culture (SILAC) quantitative mass 
spectrometry combined with a fractionation protocol to investigate the role of ATM kinase 
activity in DNA damage-induced spatial protein dynamics.122 
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4.3 METHODS 
4.3.1 Cell culture 
IMR90 and U2OS cells were cultured in DMEM supplemented with 10% fetal bovine 
serum and 100 units/mL penicillin/streptomycin. In the SILAC experiment, IMR90 cells were 
grown in DMEM supplemented with 10% fetal bovine serum dialyzed with a cutoff of 10 kDa 
(Pierce, Rockford, IL) and 100 units/mL penicillin/streptomycin. We cultured two separate 
populations of IMR90 cells in either “light” SILAC medium (supplemented with L-lysine and L-
arginine with natural abundance isotopes) or in “heavy” SILAC medium (supplemented with 
13C6-lysine and 13C615N4-arginine) (Pierce, Rockford, IL) for at least 6 passages. Cells were 
tested for full incorporation of labeled isotopes after six passages. 
4.3.2 Subcellular fractionation 
IMR90 cells cultured in “light” and “heavy” SILAC medium were plated with equal cell 
numbers into three 60 mm petri dishes (6 total dishes). The next day, both cell populations were 
γ-irradiated with 2 Gy in a Shepherd Mark I Model 68 [137Cs] irradiator (J.L. Shepherd & 
Associates, San Fernando, CA) at a dose rate of 78.3 R/min.  At +15 minutes post-irradiation, 
KU55933 (KuDOS Pharmaceuticals) was added to the cells grown in “heavy” media so that the 
final concentration of KU55933 was 10 µM. The equivalent volume of DMSO (vehicle control) 
was added to the cells grown in “light” media.   
At +75 minutes post-irradiation, the cells from both populations were washed twice with 
PBS, and cells from both “heavy” and “light” populations were fractionated as described 
  48 
previously, with additional modifications.123-125 150 µL of Solution A [10 mM HEPES (pH 7.9), 
10 mM KCl, 1.5 mM MgCl2, 0.34 sucrose, 10% glycerol, 0.1% triton X-100] was added to each 
60 mm dish from the “heavy” and “light” populations, and the cells were scraped and collected 
into the same eppendorf tube (1:1 ratio) and incubated for five minutes on ice. Cells were 
centrifuged at 1,300 g on a Sorvall tabletop centrifuge, and the supernatant was collected as the 
cytoplasmic fraction.  
The remaining pellet was washed once with Solution A, and resuspended in 400 µL of 
Buffer MN [Solution A with 1 mM CaCl2] with four units of micrococcal nuclease (Worthington 
Biochemical Corporation, Lakewood, NJ) and the incubated in a 37°C waterbath for two 
minutes. 1mM EGTA was then added to the tube to stop the micrococcal nuclease reaction and 
the lysate was centrifuged at 1,300 g for seven minutes. The supernatant was collected and 
removed. The nuclear pellet was washed once in Solution A, then resuspended in 100 µL 
Solution B [3 mM EDTA, 0.2 mM EGTA], vortexed and allowed to incubate on ice for ten 
minutes.  The tube was centrifuged at 10,000 g for seven minutes and the supernatant was 
collected as the soluble nuclear fraction. 100 µL of modified RIPA lysis buffer [20 mM HEPES, 
137 mM NaCl, 10% glycerol, 1% triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM 
EDTA] was added to the pellet, the lysate was vortexed and incubated on ice for ten minutes. 
The tube was centrifuged at 1,000 g for ten minutes and the supernatant was collected as the 
chromatin fraction. 200 µL Laemmli buffer (Bio-Rad, Hercules, CA) was added directly to the 
remaining pellet for the insoluble fraction. Laemmli buffer was added to the cytoplasmic, soluble 
nuclear and chromatin fractions at a 1:1 volume ratio.  
Phosphatase inhibitors (sodium orthovanadate, β-glycerophosphate, sodium 
pyrophosphate, sodium fluoride), SUMOylase inhibitor (N-ethylmaleimide), 1 mM DTT and a 
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complete mini EDTA-free protease inhibitor cocktail tablet (Roche Applied Science, 
Indianapolis, IN) were added to all fractionation buffers (Solution A, Buffer MN, Solution B, 
Modified RIPA) before use. The four fractions were resolved by 1D SDS-PAGE on a NuPAGE 
Novex 4-12% Bis-Tris precast gels (Invitrogen, Carlsbad, CA). The gel was stained with 
Coomassie blue to provide a general estimation of the protein lysate integrity. The gel lane from 
each fraction was sliced into ten equivalent sized bands (four fractions * ten slices=40 total 
bands) and proteins were digested in-gel overnight with sequencing grade trypsin (Promega, 
Madison, WI). 
4.3.3 LC-MS/MS 
The extracted tryptic peptides from each of the 40 gel bands were separately analyzed in 
duplicate by nanoflow reversed-phase (RP) LC coupled online by electrospray ionization with a 
hybrid linear ion trap-Orbitrap MS (ThermoFisher Scientific, San Jose, CA).  Liquid 
chromatography was performed using a Dionex Ultimate 3000 nanoflow LC system (Dionex 
Corporation, Sunnyvale, CA). Separation of the sample was performed using a 75 µm inner 
diameter x 360 outer diameter x 45 cm-long fused silica capillary column (Polymicro 
Technologies, Phoenix, AZ) packed in house with 5 µm, 300 Å pore size Jupiter C-18 stationary 
phase (Phenomenex, Torrance, CA). After injection, the column was washed with 98% mobile 
phase A (0.1% formic acid in water) for 30 min and peptides were eluted by development of a 
linear gradient of 2% mobile phase B (0.1% formic acid in acetonitrile) to 42% mobile phase B 
in 140 min, then to 98% B in an additional 20 min, all at a constant flow rate of 250 nL/min. The 
MS was operated in a data-dependent MS/MS mode in which each full high resolution MS scan 
conducted in the Orbitrap was followed by seven MS/MS scans in the linear ion trap where the 
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seven most abundant peptide molecular ions dynamically determined from the MS scan were 
selected for tandem MS using a relative collision-induced dissociation (CID) energy of 30%. 
Dynamic exclusion was utilized to minimize redundant selection of peptides for CID. 
4.3.4 Bioinformatics 
Tandem mass spectra were searched for peptide identifications by running Inspect, 
against human IPI protein database (v3.75) with parent mass tolerance 2 Da and fragment mass 
tolerance 0:5.126 At most one modification (K+6, R+10) was allowed. To distinguish between the 
false and correct peptide identifications, false discovery rate (FDR) approach using a standard 
target/decoy strategy was employed.127 Each Inspect search result was individually filtered at 1% 
FDR. Quantification of protein abundance was be achieved by measuring the relative intensities 
of light and heavy peptides in the MS spectra, which were spaced by 6 daltons for peptides with 
Lys (K) or by 10 daltons for ones with Arg (R). Ratios were generated for each protein based on 
the corresponding peptide intensities of KU55933 to control (KU55933:vehicle) to determine the 
differential protein abundance in each fraction. Protein SILAC ratios will be determined by 
averaging all peptide SILAC ratios from all unique and common peptides identified per given 
protein. 
4.3.5 Network analyses of the chromatin fraction 
The Cytoscape NeMo algorithm was used to analyze the chromatin fraction to identify 
densely connected sub-component.128 We used the ConsensusDB protein-protein interaction 
network, which includes ~100,000 known protein-protein interactions in human cells 
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downloaded from interaction databases such as BioGRID, IntAct, and HPRD.129 Chromatin 
proteins from the screen were included in the analysis if the protein ratio fulfilled one of two 
criteria: absolute value(log2ratio) > 0.58 or pval < 0.05. 29 sub-networks were identified and the 
final networks were generated from taking the union of the 29 subnetworks. The node colors was 
used to represent relative log2ratio(KU55933/vehicle) protein abundance. Dark green nodes 
indicate a low log2ratio(KU55933/vehicle), dark red nodes indicate a high 
log2ratio(KU55933/vehicle), white nodes indicate proteins detected in the screen but were 
unchanged with KU55933 and grey nodes represent proteins which were not detected in the 
screen. 
For the DNA damage response network enrichment analysis of the chromatin fraction, 
we determined what fraction of direct neighbors in a protein interaction network are DNA 
damage response (DDR) proteins.  Chromatin proteins were included in the analyses if the 
protein ratio had a |log2ratio(KU55933:control)| > 1.5 or with a p-value for differential 
expression below 0.05 We used the ConsensusPathDB protein-protein interaction network and a 
list of 434 proteins that function in the DDR for this analysis.129 A p-value for DDR 
neighborhood enrichment was determined by an enrichment ratio: 1) # of neighbor genes 
involved in DDR/total # of neighbor genes and 2) # of DDR genes/total of # of genes in network.  
The hypergeometic distribution was used to generate a p-value for the significance of enrichment 
(distribution of ratio 1 versus distribution of ratio 2), which was corrected for multiple 
hypothesis testing using the Benjamini-Hochberg method. 
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4.3.6 Antibodies and plasmids 
Antibodies used: mouse anti-ATM (Sigma), rabbit anti-phospho S1981 ATM 
(Epitomics), rabbit anti-p53 (Santa Cruz Biotech), mouse anti-GAPDH (Abcam), mouse anti-
retinoblastoma (BD Biosciences), rabbit anti-histone H3 (Abcam), mouse anti-lamin A+C 
(Abcam) and mouse anti-53BP1 (Millipore). ms53BP1-GFP expression construct was a kind gift 
from Jiri Bartek. Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used for the transfection of 
plasmids into cells. 
4.3.7 Live cell microscopy 
GFP-mouse-53BP1 was transfected into U2OS cells using Lipofectamine 2000 
(Invitrogen) and stable expression of GFP-ms53BP1 was selected using G418 (50 µg/mL). Cells 
were plated on 35 mm round glass bottom dishes (MatTek Corp.) and incubated overnight at 
37°C with 5% CO2. The next day, the dishes were irradiated with 2 Gy of ionizing radiation 
using a [137Cs] source.  15 min post-irradiation, 10 µM KU55933 or the equivalent volume of 
DMSO (vehicle control) was added to the dishes and incubated at 37°C with 5% CO2.  At +60 
min post-irradiation dishes were placed in an environmentally controlled closed chamber system 
(Tokai Hit) which was maintained at 37°C and 5% CO2 during imaging. The chamber system 
was mounted on an inverted confocal microscope (Nikon A1, Nikon), controlled by NIS-
Elements software.  
At +75 minutes post-irradiation, time-lapse image acquisition was initiated on defined 
ionizing radiation-induced nuclear foci to obtain baseline intensities. Ionizing radiation-induced 
nuclear foci were then photobleached using a 488-laser set at 100% power, a scan speed of 1/8 
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frames per second, an exposure time of 53.57 seconds, allowing seven laser pulses to hit a 
defined region in a single nucleus. Time-lapse images were captured for 30 minutes following 
photobleaching (from +75 minutes to +105 minutes post-2 Gy IR), in 30 second intervals with 
the 488-laser set at 5% power, a scan size of 1024, a scan speed of ¼ frames per second, and a 
zoom of 1.499X. The excitation wavelength for GFP was the 488-laser and signal was collected 
through a CFI Plan Apo VC 60´ Oil objective, NA=1.40. Perfect focus system (PFS) was applied 
to automatically correct possible focus drift during the period of time-lapse imaging. Post-
acquisition processing of image files was performed with NIS-Elements software. We performed 
a double normalization to correct for acquisition bleaching for each region of interest (ROI).130 
The mean pre-bleach whole cell intensity of a neighboring cell expressing GFP-53BP1 was 
divided by the mean whole cell intensity of the same neighboring cell at each time point in the 
post-bleach period, and this ratio was then multiplied to the FRAP curve at respective time 
points. To correct for background intensity, the mean intensity of a background ROI was 
subtracted from the neighboring cell ROIs and FRAP ROIs for each timepoint. Relative intensity 
(RI) was calculated by: RI(t) = I(t)/Ipb, where Ipb is the mean intensity of the ROI before 
photobleaching. Each data point was derived from the mean intensities of 5 different foci 
measurements from 5 different cells collected from 3 different experiments per condition. The 
error bars in the FRAP curve represent the standard error of the mean. 
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4.4 RESULTS 
4.4.1 SILAC and LC-MS/MS  
We grew two populations of IMR90 cells in either “light” media (DMEM supplemented 
with 12C6-lysine and 12C614N4-arginine) or “heavy” media (DMEM supplemented with 13C6-
lysine and 13C615N4-arginine) to differentially label proteins with isotopes that can be 
distinguished using mass spectrometry (Figure 12).122,131 Growth in heavy media had no effect 
on ATM kinase signaling in irradiated cells (Figure 12). KU55933 is a selective and reversible 
ATM kinase inhibitor that can be used to transiently inhibit ATM kinase activity in cells.19,91 We 
have previously shown that 1 hour transient ATM kinase inhibition with KU55933, from +15 
minutes to +75 minutes following 2 Gy of ionizing radiation, sensitizes cells, increases 
chromosome aberrations and abrogates sister chromatid exchange, demonstrating that sustained 
ATM kinase activity has critical functions one hour post-irradiation.19,54,91 Thus, we incorporated 
the same temporal treatment window of KU55933 into the design of the SILAC workflow. At 
+15 minutes post-irradiation, cells grown in heavy media were treated with 10 µM KU55933, 
and cells grown in light media were treated with the equivalent volume of DMSO (vehicle 
control) for one hour at 37°C.  At +75 minutes post-irradiation, both light and heavy cell 
populations were harvested, mixed at a 1:1 ratio, and fractionated using a protocol described 
previously with several modifications.123-125 Four distinct subcellular fractions were generated as 
evidenced by the immunoblot detection of the cytoplasmic protein GAPDH, the soluble nuclear 
protein retinoblastoma, the chromatin-bound protein histone H3 and the nuclear matrix/nuclear 
membrane-associated protein Lamin A+C in fractionated lysates from unirradiated IMR90 cells 
(Fig. 12).  All four fractions were separated by 1D SDS-PAGE and each gel lane was cut into ten 
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pieces, digested with trypsin, and analyzed by nanoflow reversed-phase (RP) LC coupled online 
by electrospray ionization with a hybrid linear ion trap-Orbitrap MS.                                                        
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Figure 12. SILAC workflow. 
A. We used stable isotope labeling in cell culture (SILAC) with a subcellular fractionation and high-throughput 
identification of proteins by mass spectrometry to compare the proteomes of irradiated cells treated with an ATM 
kinase inhibitor (KU55933), with irradiated cells treated with DMSO (vehicle control). B. Growth in heavy media 
had no effect on ATM kinase signaling in irradiated cells. C. Four distinct subcellular fractions were generated as 
evidenced by the immunoblot detection of the cytoplasmic protein GAPDH, the soluble nuclear protein 
retinoblastoma, the chromatin-bound protein histone H3 and the nuclear matrix/nuclear membrane-associated 
protein Lamin A+C in fractionated lysates from unirradiated IMR90 cells. 
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A total of 18,271 pairs of distinct light and heavy peptides were quantified: 11,069 peptide 
pairs from the cytoplasmic fraction, 8,591 peptide pairs from the chromatin fraction, 4,607 pairs 
from the soluble nuclear fraction and 6,796 peptide pairs from the insoluble pellet fraction. Of 
the 18,271 peptide pairs, 16,360 were unique peptides and 1,911 were common peptides shared 
by more than 1 protein. Both unique and common peptide pairs were assigned to corresponding 
proteins. The light intensity, heavy intensity and ratio of heavy:light (KU55933:vehicle) 
intensities were averaged and normalized for each peptide in a given protein.  The averaged 
ratios provided a measure of the relative abundance of the protein, such that a log2ratio <0 
indicates a decrease, log2ratio >0 represents an increase, and a log2ratio =1 represents no change 
in protein abundance with KU55933 treatment. The total number of proteins identified was 
4,196: 2,992 proteins in the cytoplasmic fraction, 1,470 proteins in the soluble nuclear fraction, 
2,240 proteins in the chromatin fraction and 1,924 proteins in the insoluble nuclear fraction 
(Figure 13). The overlap in the shared number of proteins across the four fractions is depicted in 
Figure 14. To identify proteins that significantly change with KU55933 following irradiation, an 
MA plot was constructed for each fraction to visualize the differential expression with KU55933 
treatment (Figure 15).  
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Figure 13. Distribution of proteins identified across fractions. 
The light intensities, heavy intensities and the ratio of heavy:light (KU55933:vehicle) intensities were averaged and 
normalized for each peptide in a given protein.  The averaged ratios provide a measure of the relative abundance of 
the protein, such that a log2ratio <0 indicates a decrease, log2ratio >0 represents an increase, and a log2ratio =1 
represents no change in protein abundance with KU55933 treatment. 
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Figure 14. Overlapping proteins shared between fractions.
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Figure 15. MA plots of the cytoplasmic, soluble nuclear, chromatin and insoluble pellet fractions. 
The y-axis represents the differential expression of the protein when irradiated cells are treated with KU55933 and 
the x-axis represents the relative abundance of the protein. A t-test was performed on the distribution of light peptide 
intensities and heavy peptide intensities for each protein to generate a p-value for the differential expression of each 
protein.  The pink-to-red color gradient used for the data points is a representation of the p-value generated from the 
t-test, with red indicating a smaller p-value or greater confidence in the log2ratio determined for the protein and grey 
coloring denoting that significance was not achieved. Proteins were not plotted if p-values could not be generated 
(i.e. only a single pair of intensity values were determined for a protein) or if either the light or heavy intensities for 
a peptide pair were zero. Out of the four fractions, the chromatin fraction showed the greatest number of proteins 
that changed with KU55933, as represented on the MA plot by the cluster of data points at the extreme ends of the 
y-axis 
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4.4.2 Network analyses of the chromatin fraction 
Increased chromosome aberrations and decreased sister chromatid exchange, a cytological 
manifestation of homologous recombination repair of DNA double-strand breaks, are two 
phenotypes that we observe in irradiated IMR90 cells that are treated with KU55933 +15 
minutes to +75 minutes following irradiation.19,91,107 Thus, we directed our focus onto the 
chromatin fraction to identify proteins whose retention at damaged chromatin changes with 
KU55933. Using Network Module identification (NeMo) in Cytoscape, we interrogated the 
chromatin fraction to isolate densely connected molecular interaction networks, which often 
represent protein complexes and or biological processes.128 We identified seven subnetworks 
enriched for Gene Ontology functional categories such as transmembrane receptor tyrosine 
kinase signaling, ligase activity, nuclear pore, ribonuclearprotein complex, chromatin 
remodeling, vesicles and cytosketal (Figure 16). 132 
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Figure 16. Functional subnetworks identified in the chromatin fraction. 
The NeMo algorithm and the ConsensusPathDB protein-protein interaction network was used to identify densely 
connected sub-components in the chromatin fraction. Triangle nodes designate known DNA damage response 
proteins and circle nodes designate non-DNA damage response proteins. Dark green nodes indicates a low log2ratio 
(KU55933:control) of protein abundance, while dark red indicates a high log2ratio (KU55933:control) of protein 
abundance. Grey nodes indicate proteins that were not measured in the screen. White nodes indicate proteins that 
were detected in the screen but unchanged with KU55933. 
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4.4.2.1 The 53BP1 DNA damage response network 
We further studied the chromatin fraction to look for protein that changed significantly 
with KU55933 that were also enriched for direct interactions with DNA repair proteins. Based 
on these analyses, 53BP1 (TP53BP1) was both differentially present in the chromatin and most 
significantly enriched for direct DNA damage protein neighbors, with a p-value of enrichment of 
2*10-21 (Figure 17).  The enrichment ratio for 53BP1 was 16.4 and 52.3% of its direct neighbors 
were DNA damage proteins. The retention of 53BP1 in the chromatin fraction decreased by 30% 
with KU55933 (log2ratio= -0.3) and the p-value of this differential expression was 0.0007. Using 
Cytoscape, we visualized the 53BP1 DNA damage-subnetwork (Figure 18).133 In Figure 19, we 
include a representative tandem mass spectrum of a 53BP1 peptide 
(1631SNVSSPATPTASSSSSTTPTR1651) which showed approximately 50% lower abundance in 
the KU55933-treated cells.  
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Figure 17. DNA damage neighborhood enrichment analysis of the chromatin fraction. 
For each protein, we determined what fraction of its direct neighbors in a protein interaction network are DNA 
damage response (DDR) proteins.  Chromatin proteins were included in the analyses if the protein ratio had a 
|log2ratio(KU55933:control)| > 1.5 or a p-value for differential expression below 0.05. We used the 
ConsensusPathDB protein-protein interaction network and a list of 434 proteins known to function in the DNA 
damage response for this analysis. A p-value for DNA damage neighborhood enrichment was determined by 
comparing two enrichment ratios: 1) # of neighbor genes involved in DDR/total # of neighbor genes and 2) # of 
DDR genes/total of # of genes in network.  The hypergeometric distribution was used to generate a p-value for the 
significance of enrichment (distribution of ratio 1 versus distribution of ratio 2), which was corrected for multiple 
hypothesis testing using the Benjamini-Hochberg method. 53BP1 (TP53BP1) was determined to be the protein most 
significantly enriched for direct DNA damage protein neighbors, with a p-value of enrichment of 2*10-21. 
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Figure 18. The 53BP1 DNA damage response neighborhood.  
Cytoscape was used to visualize the 53BP1 DNA damage response network, which consists of 46 nodes and 268 
edges or protein-protein interactions. The green diamond-shaped nodes denote DNA damage response proteins and 
the blue circular nodes denote non-DNA damage response proteins.  
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Figure 19. Representative tandem mass spectrum of 53BP1.  
The 53BP1 peptide (1631SNVSSPATPTASSSSSTTPTR1651) shows approximately 50% lower abundance in the 
KU55933-treated cells (inset). 
 
4.4.2.2 The ANXA1 DNA damage response network 
The anti-inflammatory protein ANXA1 is also significantly enriched for protein-protein 
interactions with DNA damage proteins. The retention of ANXA1 in the chromatin fraction 
decreased with KU55933 by a log2ratio= -4.9, and the p-value of this differential expression was 
0.002. Figure 20 depicts the ANXA1 DNA damage-subnetwork, which consists of 146 nodes 
and 4,428 edges. In a plot of all the proteins identified in both the cytoplasmic and chromatin 
fractions, ANXA1 protein levels in irradiated cell does not change with KU55933, but are 
selectively decreased in the chromatin (Figure 21). Figure 22 shows the overlay of mass 
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chromatograms from the light (untreated; solid-line) and heavy (treated; dashed-line) 
isotopomeric peptide pair (189SEDFGVNEDLADSDAR204) identified from annexin A1.  
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Figure 20. The ANXA1 DNA damage response neighborhood. 
Cytoscape was used to visualize the ANXA1 DNA damage response network, which consists of 146 nodes and 4,428 edges or protein-protein interactions. The 
green diamond-shaped nodes denote DNA damage response proteins and the blue circular nodes denote non-DNA damage response proteins. 
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Figure 21. Pair-wise comparison of cytoplasmic versus chromatin fractions.  
ANXA1 protein abundance does not change in the cytoplasm of irradiated cells when treated with KU55933, but 
changes significantly in the chromatin fraction. 
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Figure 22. Overlay of ANXA1 mass chromatograms from the cytosplamic and chromatin fractions.  
The light (vehicle; solid-line) and heavy (KU55933; dashed-line) isotopomeric peptide pair 
(189SEDFGVNEDLADSDAR204) identified from ANXA1 demonstrates an approximate equivalent abundance in the 
untreated and treated cells in the cytoplasmic fraction (A) and the lack of a detectable heavy peptide (KU55933; 
dashed line) in the chromatin fraction (B). 
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4.4.3 53BP1 chromatin dynamics 
DNA damage proteins have been shown to localize to the sites of DSB within seconds to 
minutes following ionizing radiation (IR) exposure, resulting in the formation of microscopically 
detectable nuclear domains referred to as ionizing radiation-induced foci (IRIF). 53BP1 is one of 
the earliest proteins recruited to IRIF, accumulating at DNA damage sites two to three minutes 
after damage induction.134-136 53BP1 is highly mobile in the nucleus of non-irradiated cells, 
however upon binding to IRIF, the mobility of 53BP1 is greatly reduced.137,138 53BP1 has known 
functions in non-homologous end-joining (NHEJ) of DNA double-strand breaks and in 
transducing ATM-dependent cell-cycle checkpoints.135,139-143 Recruitment of 53BP1 to DNA 
double-strand breaks is ATM-independent, but 53BP1 at DNA breaks requires γ-H2AX.136,143 In 
cells lacking 53BP1, phosphorylation of ATM substrates is reduced, suggesting that 53BP1 
functions upstream of ATM.135,141 53BP1 is also a substrate of ATM, with phosphorylation sites 
at serines 6, 25, 29 and 784, although these phosphorylation sites are dispensible for 53BP1 
localization to IRIF.143  
In our experiments, KU55933 is added to the cells +15 minutes post-irradiation, which is 
sufficient time for the rapid recruitment of 53BP1 to DNA damage sites.134-136 We have 
previously shown that transient ATM kinase inhibition with KU55933 from +15 min to +75 min 
post-irradiation does not affect the number of 53BP1 or γ-H2AX foci when measured at +75 
minutes, +6 hours and +12 hours post-irradiation in cells fixed with paraformaldehyde91 We 
repeated the fractionation protocol in irradiated IMR90 cells in order to validate by immunoblot 
that 53BP1 chromatin retention is reduced with KU55933 (Figure 23). Thus, the LC-MS/MS and 
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immunoblots of chromatin fraction lysates indicate that 53BP1 is reduced in the chromatin 
fraction in irradiated cells treated with KU55933.  
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Figure 23. Immunoblot validation of 53BP1 differential expression in chromatin with KU55933.   
A. Fractionation chromatin lysates from irradiated IMR90 cells show that 53BP1 chromatin retention is reduced 
with KU55933. An image of the nitrocellulose membrane stained with fast green is included to demonstrate equal 
loading of the chromatin fraction lysates. B. ImageJ quantification of immunoblots show 28% reduction in 53BP1 n 
the chromatin fraction in irradiated cells when treated with KU55933. The experiment was performed three separate 
times, and the error bars reflect the standard deviation.  
A. B. 
anti-53BP1
2G
y 
ve
hi
cl
e
2G
y 
KU
55
93
3
  78 
  
 
 
Figure 24. U2OS cells transfected with the msGFP-53BP1 construct expresses intact ms53BP1.  
Immunoblots show that GFP-ms53BP1 transfected into U2OS cells (left immunoblot) migrates to a similar 
molecular weight as endogenous human 53BP1 on 1D SDS-PAGE (right immunoblot). 
 
We hypothesized that KU55933 increases the mobility of 53BP1 at IRIF, such that 
53BP1 protein complexes are destabilized at IRIF. To test this, we performed fluorescence 
recovery after photobleaching (FRAP) experiments to analyze the dynamics of IRIF-associated 
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GFP-53BP1. U2OS cells transfected with GFP-ms53BP1 were irradiated with 2 Gy and treated 
with either DMSO (vehicle control) or KU55933 for +15 minutes to +75 minutes post 
irradiation.144 We performed immunoblots to show that the GFP-ms53BP1 construct is intact 
(Figure 24). We see that the extent of fluorescence recovery of GFP-m53BP1 in irradiated cells 
treated with vehicle control was approximately 90%, whereas the extent of fluorescence recovery 
in irradiated cells treated with KU55933 was approximately 70% (Figure 25). We interpret this 
data to mean that immediately after photobleaching, GFP-53BP1 rapidly diffuses throughout the 
photobleached area. The rapid diffusion of GFP-53BP1 occurs similarly in the vehicle- and the 
KU55933-treated cells as indicated by the similar slopes of the vehicle and KU55933 FRAP 
curves, immediately after photobleaching. These early interactions represent transient 
interactions of GFP-53BP1 at IRIF. The decrease in the rate of recovery of GFP-53BP1 in 
irradiated cells treated with KU55933 likely represents the decrease in the strength of GFP-
53BP1 binding at IRIF, such that over time the off-rate of GFP-53BP1 at binding sites located at 
IRIF is increased with KU55933.  
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Figure 25. FRAP analysis of GFP-53BP1.  
A. Representative timecourse of images of GFP-m53BP1 in irradiated U2OS cells expressing GFP-53BP1 and 
treated with 10 µM KU55933 or vehicle control from +15 to +75 minutes following 2 Gy IR. The photobleached 
regions are designated by the arrows. B. FRAP analysis of GFP-m53BP1. At +75 min post-irradiation, a 488 pulse 
laser was used at 100% power, which allowed photobleaching of GFP-ms53BP1 IRIF without inducing DNA 
damage. From +75 minutes to +105 minutes post-irradiation (30 minute duration), the fluorescence recovery of the 
GFP-ms53BP1 foci was measured every 30 seconds. Next, we used FRAP to analyze the IRIF-associated GFP-
m53BP1 in irradiated cells treated with or without KU55933. U2OS cells stably expressing GFP-m53BP1 were 
exposed to 2 Gy of  γ-rays from a [137Cesium] source and incubated for 15 minutes at 37 degrees prior to adding 10 
µM KU55933 or DMSO (vehicle control) for 1 hour (+15 minutes to +75 minutes post-irradiation). At +75 minutes 
post-irradiation, we used a 488 pulse laser at a power that did not induce DNA damage to photobleach IRIF. The 
relative fluorescence intensity curve was plotted using the mean of five IRIF, each in a different nucleus from five 
different cells derived from three different experiments. Error bars reflect standard error of the mean. 
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4.5 CONCLUSION 
The spatial dynamics of proteins in response to DNA damage is critical to genome 
stability.69,119-121 Here, we developed a novel high throughput proteomics approach to identify 
protein dynamics that are regulated by ATM kinase activity following irradiation. Although 
studies exploring the ATM kinase-dependent phosphoproteome following DNA damage have 
been performed, studies on global ATM kinase-dependent spatial proteome dynamics following 
DNA damage have not been reported.20-22 Knowledge of the subcellular distribution of proteins 
within cells and how the spatial distribution changes in response to DNA damage is generally 
lacking. Recently, Boisvert et. al. used SILAC-based mass spectrometry to analyze a whole cell 
extract created by recombining differentially labeled cytoplasmic, nuclear, and nucleolar 
fractions derived from cells in which proteins have been mass-labeled with three different heavy 
isotope labels.145,146 This approach, termed “spatial proteomics,” provides an innovative method 
of quantitatively mapping the proteomes of the subcellular compartments and capturing the 
dynamic protein movement that occurs between subcellular compartments, particularly following 
treatment with etoposide.145 Here, we provide an alternative method to that of Boisvert et. al. that 
allows the investigation of additional subcellular compartments to the cytoplasmic, nuclear, and 
nucleolar fractions, such as the chromatin fraction, which is particularly relevant for studies on 
the DNA damage response. 
In a comparison between the cytoplasmic and chromatin fractions, we found that the anti-
inflammatory protein ANXA1 exhibits a dramatic decrease in protein abundance in the 
chromatin fraction when ATM kinase activity was inhibited, whereas loss of sustained ATM 
kinase activity did not affect the levels of ANXA1 in the cytoplasmic fraction. Interestingly, a 
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previous study demonstrated that ANXA1 translocates from the cytoplasm to the nucleus 
following heat-induced DNA damage.147 It is tempting to speculate that ANXA1 translocation 
may also occur in response to radiation-induced DNA damage and that radiation-induced 
translocation or chromatin stabilization of ANXA1 may be regulated by ATM kinase activity. In 
our studies, ANXA1 did not change in the cytoplasmic fraction of irradiated cells with 
KU55933, but ANXA1 levels decreased significantly with KU55933 in the chromatin fraction.  
It is possible that there is a small amount of ANXA1 that moves to the nucleus following 
irradiation in an ATM kinase-dependent manner, but the corresponding reduction from the 
cytoplasmic pool cannot be detected because of the significantly greater levels of ANXA1 in the 
cytoplasm fraction versus in the chromatin fraction. If this is determined to be the case, then 
ANXA1 localization may be a useful biomarker for radiation exposure. Further studies are 
needed to determine the functions of ANXA1 at chromatin in response to genotoxic stress. 
In an analysis of the chromatin proteome, we discovered reduced 53BP1 retention in the 
chromatin fraction when ATM kinase inhibited is inhibited from +15 minutes to +75 minutes 
post-irradiation. 53BP1 is a nuclear protein that undergoes a dynamic interaction with chromatin 
in undamaged cells. Following DNA damage, the interaction of 53BP1 with chromatin increases 
due to its immobilization at and around DNA double-strand breaks.137,138 We studied the protein 
dynamics of GFP-53BP1 using live cell microscopy imaging and FRAP analysis and show that 
the fluorescence recovery of GFP-53BP1 at photobleached ionizing radiation-induced foci (IRIF) 
is decreased in cells treated with KU55933 +15 minutes to +75 minutes post-2 Gy IR (70% 
recovery) compared to irradiated cells treated with the vehicle control (90% recovery).  These 
data indicate that the exchange of 53BP1 at IRIF is impaired when ATM kinase activity is 
inhibited. Immunoblots of fractionated lysates show that 53BP1 levels in the chromatin fraction 
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of irradiated cells are also decreased with KU55933, which argues against photobleached GFP-
53BP1 being trapped at chromatin as explanation for the decrease in fluorescence recovery of 
GFP-53BP1 foci. Rather, it appears that ATM kinase inhibition disrupts the dynamic interaction 
of 53BP1 with chromatin such that 53BP1 binding or retention at chromatin is impaired. Thus, 
sustained ATM kinase activity functions to stabilize 53BP1 protein complexes at chromatin. 
The assembly and retention of 53BP1 at doublestrand breaks requires direct interaction 
between the Tudor domain of 53BP1 and dimethylated lysine 79 of histone H3.148 While H3-
dmK79 is not a DNA damage-dependent modification, it has been suggested that chromosome 
relaxation proximal to doublestrand breaks can indirectly increase recognition and binding of 
53BP1 to chromatin at these residues.148 The retention of 53BP1 at chromatin also requires the 
ATM kinase-dependent phosphorylation of histone H2AX on serine 139.140,149 In contrast to H3-
dmK79, γ-H2AX is induced by DNA damage.150 It is possible that sustained ATM kinase 
signaling following DNA damage is required to allow 53BP1 access to H3-dmK79 through 
structural changes to the chromatin and/or that sustained ATM kinase signaling is required to 
maintain the phosphorylation of histone H2AX on serine 139 to retain 53BP1 at chromatin. We 
do not think that phosphorylation of histone H2AX on serine 139 accounts for our observations, 
however, because KU55933 reduces the chromatin retention of 53BP1 even in unirradiated 
fractionated lysates (unpublished observations).  However, further studies are needed to 
determine how 53BP1 stability at chromatin is regulated by ATM kinase activity. 
Understanding the role of ATM kinase signaling on the stability of 53BP1 repair 
complexes has clinical significance. Mutations that result in defects in homologous 
recombination repair of doublestrand breaks can predispose cells to tumorigenesis, as seen in 
BRCA1 mutant cells.151 Recently, loss of 53BP1 was shown to decrease chromosome aberrations 
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and reverse the proliferation defect of BRCA1 mutant cells.152,153 53BP1 loss reverses cisplatin 
sensitivity induced by Brca1 inactivation and was shown to restore ATM kinase-dependent 
homologous recombination repair.152,153 53BP1 deletion promotes homologous recombination 
repair of doublestrand breaks by permitting the processing of broken DNA ends into 
recombinogenic single-stranded DNA.153 Since DNA end processing has been shown to be 
dependent on ATM kinase activity, it has been suggested that ATM kinase inhibitors may be 
used in combination with a PARP inhibitor to further sensitize BRCA1 mutant cells that have 
acquired resistance to cisplatin.153 Our data shows that ATM kinase inhibition following 
irradiation disrupts the localization of 53BP1 at chromatin suggesting that in addition to 
inhibiting DNA end processing in BRCA null/53BP1 null cells, kinase-inhibited ATM may also 
reduce 53BP1 at chromatin. It would be interesting to see if kinase-dead mutations in ATM are 
found as a mechanism of resistance in BRCA1 mutant cancer cells. 
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5.0  DISCUSSION 
 
ATM kinase inhibitors have proven to be instrumental in studies of ATM kinase-
dependent functions. We showed that KU55933 and KU60019 can be used as “molecular 
switches” to selectively and transiently inhibit ATM kinase activity in cells, and that the 
immediate and reversible nature of KU55933- and KU60019-mediated inhibition enables studies 
that temporally isolate ATM kinase functions.19,91 We demonstrate the use of KU55933 in 
dissociating an ATM kinase-dependent DNA repair mechanism from an ATM kinase-dependent 
cell cycle checkpoint mechanism.91 Significantly, we found ATM kinase inhibition from +15 
minutes to +75 minutes following ionizing radiation (IR) results in severe phenotypes: KU55933 
radiosensitizes cells, increases chromosome aberrations and abrogates sister chromatid exchange 
(Figure 26).19,91,109 Surprisingly, we found that with regards to sister chromatid exchange, kinase-
inhibited ATM functions differently from loss of ATM protein.91  
To determine the global protein dynamic changes that depend on ATM kinase activity 
+15 minutes to +75 minutes post-IR, we performed a SILAC-based mass spectrometry 
proteomics screen.  Through our protein-protein interaction network analyses, we found that 
53BP1 and ANXA1 are enriched for interactions with DNA damage proteins and that the protein 
dynamics of 53BP1 is altered with transient ATM kinase inhibition. This study demonstrates the 
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use of an integrative proteomics and systems biology approach in predicting ATM kinase-
dependent spatial protein dynamics that are critical for genome stability. 
 
 
 
 
 
Figure 26. Transient kinase inhibition of ATM has long-term consequences, even after restoration of ATM 
kinase activity (removal of inhibitor).  
Treatment with KU55933 (ATMi) from +15 minutes to +75 minutes following ionizing radiation (IR) results in 
severe cellular phenotypes. At 12 hours post-IR, we observed a decrease in sister chromatid exchange (SCE), a 
cytological manifestation of homologous recombination repair of DNA double-strand breaks at the replication fork. 
At 48 hours post-IR, there is an increase in chromosome aberrations. Cell proliferation and survival are decreased at 
~10 days, as measured by clonogenic assay.
  88 
An intriguing question that arose from these studies is how does kinase-inhibited ATM 
function differently from loss of ATM protein? The finding that DNA damage-induced SCE was 
maintained in A-T cells that express no ATM protein and that the ATM kinase inhibitors had no 
effect on DNA damage-induced SCE in A-T cells, indicates that the disruption of DNA damage-
induced SCE in cells expressing ATM is not a consequence of an “off-target” effect of either 
KU55933 or KU60019.91 These data revealed for the first time that the consequences of 
inhibition of ATM kinase activity and adaptation to ATM protein disruption are distinct.91,109 We 
had considered that ATM’s known functions in cell cycle checkpoints might contribute to the 
observed defect in SCE but were unable to detect any defect in either the activation or the 
recovery of the G2/M checkpoint when ATM kinase was transiently inhibited.91 This was the 
most significant checkpoint to our analyses of SCE that was performed in mitotic cells trapped 
from 8-12 hours following insult. Any delay in G2/M checkpoint recovery following transient 
ATM kinase inhibition might have prevented cells containing SCEs entering mitosis leading to 
an apparent lack of SCE.  
We hypothesize that localization of ATM is likely key to this mechanism. Since SCE 
represents the repair of damaged DNA replication forks, we favor a model in which “kinase-
inhibited ATM” presents a physical impediment to SCE at DNA double-strand breaks (DSBs) at 
damaged replication forks.107 We speculate that kinase-inhibited ATM can localize to DSBs at 
damaged replication forks.  In fact, several mutant ATM proteins that lacked kinase activity 
against downstream substrates formed IR-induced foci in A-T cells, suggesting that ATM 
recruitment to DNA damaged-induced foci is independent of ATM kinase activity.154 However, 
we propose that once ATM kinase is recruited to DSBs at damaged replication forks, local ATM 
kinase activity is required both to phosphorylate substrates that mediate DSB repair and to allow 
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mobilization of ATM itself such that DSB repair can physically proceed (Figure 27).109 Kinase-
inhibited ATM may disrupt large-scale MRE11 complex conformational changes, impairing 
homologous recombination repair of DSBs. 
Such a mechanism, in which kinase-inhibited ATM would physically block the repair of 
replication associated DNA damage by physically impeding homologous recombination repair 
(HR), is analogous to the recent finding that 53BP1 inhibits HR in Brca1-deficient cells by 
blocking DSB end resection.153 DNA breaks in Brca1-deficient cells are aberrantly joined into 
complex chromosome aberrations by a process dependent on the nonhomologous end-joining 
(NHEJ) factors 53BP1 and DNA Ligase 4.153 Loss of 53BP1 in Brca1-mutant cells promotes 
ATM kinase-dependent processing of DSBs to produce recombinogenic single-stranded DNA 
competent for error-free repair by HR.153 In contrast, Lig4 deficiency does not rescue the HR 
defect in Brca1 mutant cells but prevents the joining of chromatid breaks into chromosome 
rearrangements.153 These results indicate that HR and NHEJ compete to process DSBs that arise 
during replication. Bunting et al. proposed that a critical function for BRCA1, and perhaps other 
factors that commit breaks to HR, might be to remove end-joining proteins such as 53BP1 from 
replication associated breaks.153 In other words, the key mechanism by which 53BP1 regulates 
the choice of HR versus NHEJ could be via inhibition of DSB resection by the physical presence 
of 53BP1 itself. Thus, it is possible that phosphorylations on 53BP1 and BRCA1, both known 
substrates of ATM, are also required for ATM mobilization at DSBs. 
In accordance with this model, we hypothesize that ATM kinase activity is associated 
with the removal of ATM protein itself and/or NHEJ proteins from replication-associated breaks.  
For instance, ATM kinase-dependent MRE11/CtIP-mediated DSB resection and/or MRE11-
mediated nucleosome displacement might facilitate the generation of nucleosome-free ssDNA 
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regions that would be incompatible with continued 53BP1 chromatin binding but accessible for 
recruitment of HR proteins.155-159 Thus, ATM kinase activity may commit replication associated 
DNA damage to HR repair through the displacement of NHEJ factors.  It is possible that kinase 
inhibition of ATM protein localized at sites of replication-associated DSBs prevents the 
displacement of ATM protein itself from these sites, leaving behind rather large physical 
impediments to repair. Furthermore, the fact that SCE is not recovered when the ATM kinase 
inhibitor is removed and ATM kinase activity restored in cells suggests that there are temporal 
restrictions to this process (possibly due to loss of substrate availability upon the restoration of 
ATM kinase activity), which when disrupted results in irreversible consequences.19,91 Live cell 
imaging studies comparing the normal GFP-tagged ATM protein dynamics and that of kinase-
inhibited GFP-tagged ATM (treated with KU55933 +15 minutes to +75 minutes post-IR) and 
kinase-inhibited GFP-tagged ATM (-15 minutes to +75 minutes post-IR) will help determine if 
this hypothesis is correct. We would predict that in cells treated with KU55933 +15 minutes to 
+75 minutes post-IR, the fluorescence recovery after photobleaching of GFP-tagged ATM is 
impaired, indicating that ATM is retained longer at doublestrand breaks when ATM kinase 
activity is inhibited +15 minutes to +75 minutes post-IR. 
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Figure 27. Inhibition of ATM kinase activity does not phenocopy A-T cells: model for ATM localization. 
In cells with functional ATM protein, DNA double-strand breaks at the replication fork can be repaired via sister 
chromatid exchange (SCE) (A). When ATM kinase activity is inhibited, SCE is disrupted, possibly via a mechanism 
that immobilizes ATM itself at the break, resulting in a physical and irreversible block to DNA double-strand break 
repair (B). A-T cells, which lack detectable ATM protein, are competent for SCE (C). SCE in A-T cells is not 
disrupted by ATM kinase inhibitors, indicating that the ATM kinase-dependent decrease in SCE in cells with normal 
ATM is not due to an off-target effect of the inhibitors (D). 
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We used a SILAC-based mass spectrometry screen to identify ATM kinase-dependent 
spatial protein dynamics that occur in irradiated cells when cells were treated with KU55933 +15 
minutes to +75 minutes post-IR. We found that ATM kinase inhibition results in decreased 
53BP1 retention at chromatin, suggesting that kinase-inhibited ATM may destabilize 53BP1 
protein complexes at sites of DNA repair. This has important clinical implications since 53BP1 
was shown to decrease chromosome aberrations and reverse the proliferation defect of BRCA1 
mutant cells.152,153 This suggest that ATM kinase inhibition post-irradiation can be used to mimic 
the loss of 53BP1 in cells with mutant BRCA1. The SILAC screen also implicated ANXA1 in 
DNA repair, which may function as a biomarker for radiation damage, demonstrating the power 
of proteomics and systems biology in identifying novel candidate biomarkers for cancer therapy. 
Future studies on ANXA1 and it role on genomic stability following DNA damage are needed.  
For instance, does ANXA1 actually have a function in DNA repair? Determining the effects of 
ANXA1 depletion on radiosensitization, chromosome aberrations and sister chromatid exchange 
would be incredibly informative, as well as understanding the biological significance of ANXA1 
translocation from the cytoplasm to the nucleus and the significance of its retention at chromatin.  
Also, what is the relationship between ATM kinase activity and ANXA1? Determining 
the nature of this interaction may have important clinical implications. ANXA1 is involved in the 
constitutive nuclear factor-κB (NF-κB) activation seen in solid tumors, and suppression of 
ANXA1 in highly metastatic breast cancer cells prevents migration and metastasis.160 ANXA1 
can bind to and interact with components of the NF-κB pathway, IKKγ or NEMO, in 
immunoprecipitation studies, and silencing of ANXA1 prevents the interaction of NEMO and 
RIP1 suggesting that ANXA1 is critical for the activation of NF-κB.160 Importantly, ATM 
activates the NF-κB pathway, which regulates genes involved in the inhibition of apoptosis and 
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promotion of cell survival in response to DNA damage.161-164 ATM-induced NF-κB signaling is 
implicated in enabling cancer cells to survive genotoxic therapy.165 ATM has been shown to 
mediate cell fate via the NF-κB pathway by mediating the interaction of NEMO, RIP1, FADD, 
and caspase-8, leading to caspase activation.166 Therefore, it is possible that ANXA1 functions in 
the ATM-dependent activation of NF-κB signaling and that ANXA1 can be targeted to modulate 
cell fate following genotoxic therapy. 
The ATM and ANXA1 interaction discovered through the SILAC screen may have also 
revealed a plausible explanation for the ATM kinase-dependent abrogation of sister chromatid 
exchange (SCE). It is possible that ATM kinase inhibition +15 minutes to +75 minutes post-IR 
destabilizes the SLX4-SLX1 protein complex, which is required for the cleavage of Holliday 
junctions, preventing the formation of crossover products of homologous recombination 
repair.167,168 In the SILAC screen we discovered that KU55933 results in a dramatic decrease in 
chromatin-bound ANXA1 in irradiated cells. The DNA repair neighborhood network analyses 
performed on the chromatin fraction revealed that ANXA1 is significantly enriched for DNA 
repair proteins. The strongest interaction revealed by these analyses was that ANXA1 binds 
directly to the DNA repair protein SLX1 (GIYD1). SLX1, which forms a complex with SLX4, 
functions as a structure specific endonuclease, which recognizes and cleaves DNA structures that 
are formed as intermediates in homologous recombination repair of DNA double-strand breaks 
(DSBs).110,167,168 In addition to SLX1, SLX4 forms multi-protein complexes with two other 
structure-specific endonucleases (ERCC4-ERCC1 and MUS81-EME1), the mismatch repair 
complex MSH2-MSH3, components of the telomere shelterin complex TRF2-RAP1, C20orf94 
and PLK1.168 Depletion of SLX4 reduces the efficiency of repair of I-SceI-induced DSBs by 
25% in human cells, demonstrating that SLX4 functions in homologous recombination repair.168 
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Pertinent to the molecular mechanism of SCE, the SLX1-SLX4 module promotes cleavage of 
double Holliday Junctions (HJ). HJs are four-stranded structures involving two homologous 
DNA duplexes that must be resolved into linear duplexes, which are produced during the 
homologous recombination repair of DNA double-strand breaks.43,169  
The cleavage of Holliday junctions is a necessary step in the formation of SCE. The 
common steps of homologous recombination repair of a DNA double-strand break are 
processing of a DNA double-strand break to give single-strand DNA (ssDNA), formation of a 
filament on the ssDNA ends, strand invasion into a homologous sequence to form a D-loop and 
DNA polymerase extension.43 Homologous recombination repair can be further subdivided into 
three sub-pathways: gene conversion, single-strand annealing, and break-induced 
replication.43,170 If both ends of the DSB are present, then the damage is repaired by gene 
conversion using one of three mechanisms: DNA double-strand break repair involving Holliday 
junction resolvase-dependent processing of the junction, double Holliday junction dissolution 
involving Bloom helicase-dependent branch migration and topoisomerase-dependent 
decatenation of the junction, or synthesis-dependent strand annealing, which does not involve 
dHJ structures (Figure 28).43,170 Two types of repair products result, depending on the 
mechanism employed: crossovers, in which DNA strands are exchanged relative to the initial 
chromosome organization, and noncrossovers, where no DNA strand exchange occurs.43,170 
DNA double-strand break repair generates both crossover or noncrossover products, while SDSA 
and HJ dissolution generate noncrossover products (Figure 28).43,170 SCE is a process whereby 
two sister chromatids break and rejoin with one another, physically exchanging regions of the 
parental strands in the duplicated chromosomes, thus, SCE is a manifestation of a crossover 
event.107  
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Figure 28. Sub-pathways of homologous recombination repair of DSBs that result in crossovers.  
Double-strand break repair can generate either crossover or noncrossover products, while Synthesis Dependent 
Strand Annealing and HJ dissolution generate only noncrossover products. 
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Recently, the SLX4-SLX1 complex was reported to promote SCE. In Bloom’s syndrome 
cells, which are defective for Holliday junction dissolution and harbor abnormally high SCEs, 
the depletion of SLX4 was shown to reduce the frequency of SCEs, indicating that the SLX4-
SLX4 module promotes SCE formation.171 It is possible that the loss of ANXA1 retention in the 
chromatin fraction identified in the SILAC screen serves as a biomarker for the loss of the SLX-
SLX4 protein complex at the chromatin, since ANXA1 binds directly to SLX1.  I hypothesize 
that ATM kinase inhibition destabilizes SLX1-SLX4 complexes at the chromatin, preventing the 
formation of homologous recombination repair crossover products and this results in the 
abrogation of SCE. It would be interesting to see if the chromatin retention of SLX1 and SLX4 
are decreased in irradiated cells treated with KU55933 +15 minutes to +75 minutes post-IR. 
Furthermore, FRAP studies on GFP-SLX1 and GFP-SLX4 would reveal whether protein 
dynamics of the SLX4-SLX1 complex is disrupted in irradiated cells with KU55933. GFP-
tagged SLX4 protein has already been found to colocalize with γH2AX, in U2OS and HT1080 
cells, in response to DNA damage demonstrating that SLX4-SLX4 is recruited to DNA damage-
induced foci.168  
Interestingly, SLX4 was also identified as a target of the ATM/ATR protein kinase in 
irradiated human cells.21 SLX4 is also phosphorylated by the yeast orthologs of ATM and ATR, 
Tel1 and Mec1.172 Thus, SLX4 may be the ATM kinase substrate phosphorylation that is 
essential for promoting IR-induced SCE. Future studies on the effect of SLX4 phosphorylation 
mutants on radiosensitivity, chromosome aberrations and IR-induced SCEs in cells treated with 
KU55933 would help determine the function(s) of the ATM phosphorylation sites on SLX4.  
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The status of the chromatin environment is another consideration that may contribute to 
the effect of ATM kinase inhibition on SCE. ATM kinase activity is required to phosphorylate 
KAP-1 resulting in the relaxation of heterochromatin.173 In G2 cells, ATM and Artemis are 
reported to function in homologous recombination repair of DNA double-strand breaks at 
heterochromatin.103 Perhaps the loss of ATM kinase signaling +15 minutes to +75 minutes post-
IR abrogates SCE specifically at heterochromatin. It would be interesting to determine the effect 
of ATM kinase inhibition +15 minutes to +75 minutes post-IR on SCE in Artemis-depleted and 
KAP-1-depleted cells and to determine if ATM promotes SCE specifically at sites of 
heterochromatin.  
This has been an exciting time to study ATM.  With development and availability of 
ATM kinase inhibitors, I have been able to study ATM kinase activity in a way that was never 
previously possible.  As the bioavailability of the compounds improve, we may finally be able to 
determine the efficacy of ATM kinase inhibitors in humans as anti-cancer agents. ATM kinase 
inhibitors are promising as strategies for cancer therapy. Many cancer cells acquire a defect in a 
DNA repair pathway early during tumor development, which can promote additional mutations 
that are necessary for most normal cells to become transformed. As a result, the multiplicity of 
DNA repair pathways that function in normal cells is often not available in cancer cells, and thus 
cells are crippled when these residual repair pathways are inhibited. Inhibitors of ATM kinase 
activity could be effective in eliminating cancer cells that express functional ATM protein and 
also have compromised DNA repair pathways.  These cells are expected to have higher basal 
levels of replicative stress and are likely sensitive to ATM kinase inhibitors, since they are 
expected to be more reliant on ATM kinase-mediated SCE for DNA repair.  
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Several studies have already documented numerous synthetic lethal interactions with 
inhibition of ATM kinase activity.69-72 Future studies are needed to further elucidate the 
mechanisms underlying these synthetic lethal interactions. Furthermore, genome-wide siRNA 
screens to identify synthetic lethal interactions with ATM kinase inhibition in human cells would 
provide an incredible resource for guiding the rationale use of ATM kinase inhibitors as anti-
cancer agents. It will be interesting to see what new synthetic lethal relationships with ATM 
kinase inhibitors are uncovered in the future, and how they change the way we envisage the use 
of these compounds. 
The studies described in this thesis demonstrate the utility of ATM kinase inhibitors in 
determining temporal and spatial functions of ATM.  We demonstrate that timing is absolutely 
critical. Loss of ATM kinase activity +15 minutes to +75 minutes post-IR results in 70% of the 
maximal radiosensitization seen with ATM kinase inhibition 17 hours post-IR inhibition, and is 
significantly more radiosensitizing than a -15 minutes to +45 minutes post-IR inhibition 
window.19 This alone suggests that when ATM kinase inhibitors are administered in the clinic 
relative to radiation treatment can affect the efficacy of ATM kinase inhibitors. The spatial 
dynamics of proteins are also important.  How the movement and localization of proteins are 
affected by loss of ATM kinase activity is clinically significant. Several of the protein 
movements identified in the SILAC screen could be powerful functional biomarkers of genome 
instability. The rationale and novel design of our screen provides a model for future studies 
aimed at identifying functional biomarkers of radiosensitivity and genome instability. 
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